Gastroenteritis
Gastroenteritis - Summary
Gastroenteritis is a transient disorder due to enteric infection with viruses, bacteria, or protozoa. It is characterized by the sudden onset of diarrhoea, with or without vomiting.
About 20% of the UK population develop gastroenteritis each year.
The risk of complications (such as dehydration and electrolyte disturbance, haemolytic uraemic syndrome, and malnutrition) is greatest at the extremities of life, in people with concurrent chronic disease, and in those who are immunocompromised.
Gastroenteritis is characterized by sudden onset of diarrhoea. Other symptoms include sudden onset of vomiting, blood or mucus in stool, and fever or malaise.
The diagnosis of gastroenteritis is usually made on the basis of clinical symptoms and signs, but examination and culture of a stool sample may be necessary to determine the cause.
Alternative diagnoses include non-gastrointestinal infections, gastrointestinal conditions such as irritable bowel syndrome, adverse drug reaction or laxative abuse, endocrinopathy, and secretory tumours.
Adequate fluid intake should be maintained to prevent dehydration. In children this may include the use of oral rehydration salt (ORS) solution.
Children should not attend any school or other childcare facility while they have diarrhoea or vomiting, and for at least 48 hours after the last episode of diarrhoea or vomiting.
If the person is vomiting and unable to retain oral fluids or they have features of shock, severe dehydration, or an alternative life-threatening diagnosis (e.g. a child seems to be very ill, has a non-blanching rash, or has severe breathing difficulty) they should be urgently admitted to hospital.
Antidiarrhoeal and anti-emetic drugs are not usually necessary for management of gastroenteritis in primary care.
Antibiotics are not recommended for acute diarrhoea of unknown pathology, but may be required if:
The person has recently been abroad.
Stool culture reveals a causative organism.
Suspected cholera, infectious bloody diarrhoea, haemolytic uraemic syndrome, and food poisoning should be notified to the Local Authority Proper Officer.
Have I got the right topic?
This CKS topic covers the management of gastroenteritis (including presumed infectious gastroenteritis) in adults and children. Prevention of gastroenteritis is covered only briefly.
This CKS topic covers the management of people returning to the UK with traveller's diarrhoea. Advice for before the person travels, and empirical treatment for use abroad, is covered in the CKS topic on Diarrhoea - prevention and advice for travellers.
This CKS topic does not cover the management of gastroenteritis caused by Clostridium difficile. This is covered in the CKS topic on Diarrhoea - antibiotic associated.
This CKS topic does not cover the management of other causes of acute diarrhoea or the management of gastroenteritis in neonates younger than 1 month of age. Although the management of people with gastroenteritis due to food poisoning is covered, this topic does not cover the epidemiological investigations necessary to identify the source of an outbreak of food poisoning.
There are separate CKS topics on GI (lower) cancer - suspected, GI (upper) cancer - suspected, Irritable bowel syndrome, Nausea/vomiting in pregnancy, and Palliative cancer care - nausea & vomiting.
The target audience for this guidance is healthcare professionals working within the NHS in the UK who are providing first-contact or primary health care.
How up-to-date is this topic?
How up-to-date is this topic?
Changes
February 2013 — minor update. The 2013 QIPP options for local implementation have been added to this topic [NICE, 2013].
October 2012 — minor update. The 2012 QIPP options for local implementation have been added to this topic [NPC, 2012].
August 2011 — minor update. Text changed to include advice on the management of acute bloody diarrhoea potentially caused by vero cytotoxin-producing Escherichia coli in children [HPA, 2011]. Several minor typographical errors corrected. Issued in September 2011.
May 2011 — minor update. The 2010/2011 QIPP options for local implementation have been added to this topic [NPC, 2011]. Issued in June 2011.
March 2011 — topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.
August 2010 — minor update. Following a recent outbreak of E coli 0157 at an open farm in the UK, the Health Protection Agency has reminded prescribers that children with bloody diarrhoea should be admitted to hospital, to confirm the diagnosis and prevent the spread of infection to others in the household [Independent Investigation Committee, 2010]. Issued in August 2010.
April 2010 — minor update. New notifiable diseases advice has been issued by the Department of Health [DH, 2010]. Issued in April 2010.
July to September 2009 — converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.
The information on prevention of traveller's diarrhoea and management of a person with Clostridium Difficile infection are now in separate CKS topics.
Together with the updated CKS topics on Diarrhoea - antibiotic associated and Diarrhoea - prevention and advice for travellers, this CKS topic replaces the former topic on Gastroenteritis.
Previous changes
November 2008 — minor update to the text to amend advice regarding the assessment and investigation of pregnant women with gastroenteritis. Issued in December 2008.
July–September 2006 — reviewed. Validated in December 2006 and issued in January 2007.
July 2007 — minor update to the text to include advice regarding the assessment and investigation of pregnant women with gastroenteritis.
January 2006 — minor update. Nalidixic acid tablets discontinued and prescriptions have been removed. Issued in February 2006.
June 2003 — reviewed. Validated in September 2003 and issued in October 2003.
January 2000 — rewritten. Validated in March 2000 and issued in May 2000.
October 1998 — written.
Update
New evidence
Evidence-based guidelines
Evidence-based guidelines published since the last revision of this topic:
HPA (2010) Guidance on infection control in schools and other childcare settings. Health Protection Agency. www.hpa.org.uk [Free Full-text]
NICE has produced an evidence summary on new medicines for acute diarrhoea in adults:
NICE (2013) ESNM11: acute diarrhoea in adults: racecadotril. National Institute for Health and Care Excellence. www.nice.org.uk [Free Full-text]
HTAs (Health Technology Assessments)
No new HTAs since 1 May 2009.
Economic appraisals
No new economic appraisals relevant to England since 1 May 2009.
Systematic reviews and meta-analyses
Systematic reviews published since the last revision of this topic:
Bernaola Aponte, G., Bada Mancilla, C.A., Carreazo Pariasca, N.Y., et al. (2010) Probiotics for treating persistent diarrhoea in children (Cochrane Review). The Cochrane Library. Issue 11. John Wiley & Sons, Ltd. www.thecochranelibrary.com [Free Full-text]
Carter, B., and Fedorowicz, Z. (2012) Antiemetic treatment for acute gastroenteritis in children: an updated Cochrane systematic review with meta-analysis and mixed treatment comparison in a Bayesian framework. BMJ Open 2(4), e000622. [Abstract] [Free Full-text]
Christopher, P.R.H., David, K.V., John, S.M., and Sankarapandian, V. (2009) Antibiotic therapy for Shigella dysentery (Cochrane Review). The Cochrane Library. Issue 4. John Wiley & Sons, Ltd. www.thecochranelibrary.com [Free Full-text]
Soares-Weiser, K., MacLehose, H., Ben-Aharon, I., et al. (2010) Vaccines for preventing rotavirus diarrhoea: vaccines in use (Cochrane Review). The Cochrane Library. Issue 5. John Wiley & Sons, Ltd. www.thecochranelibrary.com [Free Full-text]
Primary evidence
No new randomized controlled trials published in the major journals since 1 May 2009.
Observational studies has been since the last revision of this topic:
Clark, W.F., Sontrop, J.M., Macnab, J.J., et al. (2010) Long term risk for hypertension, renal impairment, and cardiovascular disease after gastroenteritis from drinking water contaminated with Escherichia coli O157:H7: a prospective cohort study. BMJ 341, c6020. [Abstract] [Free Full-text]
Gradel, K.O., Nielsen, H.L., Schonheyder, H.C., et al. (2009) Increased short and long term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology 137(2), 495-501. [Abstract]
New policies
No new national policies or guidelines since 1 May 2009.
New safety alerts
No new safety alerts since 1 May 2009.
Changes in product availability
No changes in product availability since 1 May 2009.
Goals and outcome measures
Goals
The goals for managing acute gastroenteritis are to:
Accurately assess the person's level of dehydration and risk of complications
Appropriately admit to hospital those people with more severe dehydration
Empower patients, and parents or carers of young patients:
To seek medical care appropriately
To prevent dehydration and treat mild dehydration
To reduce the risk of transmission to others
Reduce the risk to others by early recognition and institution of infection-control measures for:
Acute infectious gastroenteritis
Food poisoning
Dysentery
QIPP - options for local implementation
QIPP - options for local implementation
Antibiotic prescribing — especially quinolones and cephalosporins
Review and, where appropriate, revise current prescribing practice and use implementation techniques to ensure prescribing is in line with Health Protection Agency (HPA) guidance.
Review the total volume of antibiotic prescribing against local and national data.
Review the use of quinolones and cephalosporin prescribing against local and national data.
Background information
Definition
What is it?
Gastroenteritis is a transient disorder due to enteric infection with viruses, bacteria, or protozoa. It is characterized by the sudden onset of diarrhoea, with or without vomiting [National Collaborating Centre for Women's and Children's Health, 2009].
Acute diarrhoea is defined as three or more episodes of partially-formed or watery stool in a day, lasting for less than 14 days [HPA, 2007a].
Food poisoning is defined by the UK Government's Advisory Committee on the Microbiological Safety of Food as 'any disease of an infectious or toxic nature caused by or thought to be caused by the consumption of food or water' [PHLS Advisory Committee on Gastrointestinal Infections, 2004]. Organisms which can be associated with food poisoning commonly include Salmonella (non-typhoidal) serotypes, Norovirus, Toxins, Campylobacter, and Escherichia coli 0157. Less commonly implicated are Bacillus species, Cryptosporidium, Entamoeba histolytica (amoebiasis), Giardia, and Shigella.
Dysentery is an acute infectious gastroenteritis characterized by loose stools with blood and mucus [World Gastroenterology Organisation, 2008], often accompanied by pyrexia and abdominal cramps. Organisms that can cause bloody diarrhoea include Campylobacter, Entamoeba histolytica, Escherichia coli, Salmonella serotypes, and Shigella.
Traveller's diarrhoea is diarrhoeal disease starting during, or shortly after, foreign travel. The organisms that most commonly cause traveller's diarrhoea are Escherichia coli, Salmonella, Viruses, Cryptosporidium, and Giardia. Dysentery and cholera are less common causes of diarrhoea in travellers. A specific pathogen can be identified in only about 50% of cases of traveller's diarrhoea.
Antibiotic-associated diarrhoea is increasingly common. A frequent causative organism is Clostridium difficile. For more information, see the CKS topic on Diarrhoea - antibiotic associated.
Causes
Which organisms can cause gastroenteritis?
Gastroenteritis is more commonly caused by viruses than by bacteria or parasites.
Viruses
Viruses
Acute gastroenteritis in children is most commonly caused by a viral infection, usually rotavirus [HPA, 2009n]. Adenovirus and rotavirus are much less common in teenagers than in younger children.
Adenovirus
Adenovirus
Adenoviruses commonly cause infections of the respiratory system, but can also cause gastroenteritis, particularly in children [World Gastroenterology Organisation, 2008].
Enteric adenoviruses (types 40 and 41) are considered to be the second most common cause of viral gastroenteritis in young children (mostly younger than 2 years of age) [Lennon et al, 2007].
Norovirus
Norovirus
Noroviruses (family Caliciviridae) are a group of single-stranded RNA viruses that cause acute gastroenteritis in humans. Norovirus has been approved as the official genus name for the group of viruses provisionally described as 'Norwalk-like viruses' and 'Norwalk virus'. Noroviruses are also known as 'small round-structured viruses' (SRSV).
Norovirus is the most common cause of viral infectious gastroenteritis in adults in England and Wales.
In contrast to rotavirus, norovirus is found in people of all ages, because immunity to it is not long-lasting.
Symptoms of norovirus infection begin 24–48 hours after infection, and last for 12–60 hours. Nausea is followed by watery diarrhoea. Vomiting may also be a feature. Some people have a raised temperature, headache, and aching limbs. Most people make a full recovery within 1–2 days, but some people (usually the very young or elderly) can become very dehydrated and require hospital treatment.
The virus is easily transmitted from one person to another, usually by the faecal–oral route. It can be transmitted by contact with an infected person, by consuming contaminated food or water, or by contact with contaminated surfaces or objects. Outbreaks of norovirus gastroenteritis are common in semi-closed environments such as hospitals, nursing homes, schools, and cruise ships.
Rotavirus
Rotavirus
Rotavirus is the most common cause of infantile gastroenteritis. Almost every child in the UK will have an infection before their fifth birthday. Infection in adults is uncommon because immunity is long-lasting.
Rotavirus gastroenteritis usually starts with fever, vomiting, followed by diarrhoea. The watery diarrhoea can range from mild to severe and generally lasts for 3–9 days. Severe diarrhoea can lead to dehydration.
It is estimated that approximately 18,000 children are hospitalized annually in England and Wales due to rotavirus-related disease.
Transmission is person-to-person, by the faecal–oral route, or by environmental contamination.
In countries with a temperate climate the disease has a winter seasonal pattern, with annual epidemics occurring from November to April.
Bacteria
Bacteria
Campylobacter
Campylobacter
Campylobacteriosis is caused by bacteria of the genus Campylobacter and is the commonest reported bacterial cause of infectious intestinal disease in England and Wales. Two species of Campylobacter account for the majority of infections: C. jejuni and C. coli.
Symptoms may be absent or include diarrhoea (which may be bloody), nausea, vomiting, cramping abdominal pain, and fever. Symptoms usually occur within 2–5 days of exposure to the organism and illness typically lasts for 1 week (but may range from a few days to a few weeks).
In people with impaired immune systems, infection with Campylobacter can occasionally be life-threatening.
Although campylobacteriosis is usually associated with the consumption of undercooked meat (especially poultry), unpasteurized milk, or untreated water, the source of infection is often not found.
Escherichia coli
Escherichia coli
Escherichia coli is a Gram-negative, rod-shaped bacterium that is a common cause of diarrhoea, particularly during childhood in the developing world, and traveller's diarrhoea (see the CKS topic on Diarrhoea - prevention and advice for travellers). Most strains of E. coli live harmlessly in the intestines of healthy humans and animals.
From a public health point of view, the most important strains are enterohaemorrhagic E. coli, known as VTEC (verocytotoxin-producing E. coli, also known as E. coli O157:H7). VTEC organisms produce a toxin that causes severe illness.
E. coli O157:H7 is a relatively rare cause of infectious gastroenteritis in the UK.
However, the haemorrhagic colitis it causes can be severe or fatal, particularly in infants, young children, and elderly people.
Approximately 5–10% of affected people develop haemolytic uraemic syndrome (HUS) 7–10 days after the diarrhoea. HUS has a case-fatality rate of about 10%.
The organism is transmitted by contaminated foodstuffs including beef and beef products (for example undercooked beef burgers), milk, and vegetables.
It can also be transmitted by contact with infected animals (especially cattle, sheep, goats, and other ruminants) on farms or in animal sanctuaries. Scrupulous hand washing after contact with any farm animal reduces the risk of transmission.
It can be spread from person to person by direct contact (faecal–oral route), particularly in households, nurseries, and infant schools.
[HPA, 2007b; CDC, 2008c; HPA, 2009e; Independent Investigation Committee, 2010; HPA, 2011]
Salmonella (non-typhoidal)
Salmonella (non-typhoidal)
Non-typhoidal salmonellosis is caused by Salmonella, a Gram-negative bacterium. The most common pathogenic serotypes are S. typhimurium and S. enteritidis.
The majority of cases of salmonellosis are sporadic, but outbreaks occur in the general population and in institutions.
It is transmitted through infected animal or human faeces that contaminate the environment, food, or water. Foodstuffs most commonly implicated in transmitting Salmonella are red and white meats, raw eggs, milk, and dairy products.
Typical features of salmonellosis are watery and sometimes bloody diarrhoea, abdominal pain, headache, nausea, vomiting, and fever occurring 12–72 hours after infection. The illness usually lasts for 4–7 days, and people usually recover without specific treatment. The disease is most likely to be severe in elderly people, infants, and people with impaired immune systems.
Complications of salmonellosis include septicaemia, and focal infections such as septic arthritis.
Shigella
Shigella
Shigellosis (also called bacillary dysentery) is caused by four species of Gram-negative, rod-shaped bacteria that are closely related to Escherichia coli: Shigella dysenteriae, S. flexneri, S. boydii and S. sonnei.
Shigellosis is primarily a disease of humans, and is commonly acquired by drinking water contaminated with human faeces or by eating food washed with contaminated water. Some people who are infected have no symptoms at all, but can still pass Shigella on to others.
Shigellosis occurs more commonly in young children, but infection can occur in all ages.
A day or two after infection with Shigella, most people develop diarrhoea (often with blood and mucus — dysentery), fever, and abdominal cramps. Shigellosis usually resolves in 5–7 days. In some, especially young children and elderly people, the diarrhoea can be so severe that the person needs to be hospitalized.
A serious complication of shigellosis is haemolytic uraemic syndrome (HUS), a disease primarily of infancy and early childhood. The Shiga and Shiga-like toxins, produced by some strains of S. dysenteriae and E. coli O157:H7, have been associated with approximately 70% of cases of HUS in children.
Toxins
Toxins
In some cases of food poisoning, the symptoms are primarily caused by toxins (rather than the organism itself) in food. Diarrhoea and vomiting usually have a rapid onset and last for less than 12 hours [Fry et al, 2005].
The bacteria most commonly implicated are:
Staphylococcus aureus — usually found in cooked meats and cream products.
Bacillus cereus — mainly found in reheated rice.
Clostridium perfringens — usually found in reheated meat dishes or cooked meats.
Foods and contaminants commonly implicated are:
Undercooked red kidney beans (vomiting, diarrhoea, abdominal pain) caused by the toxin phytohaemagglutin (kidney bean lectin), which is present in uncooked beans but is destroyed by heat.
Scombrotoxic fish poisoning — the majority of affected people have mild symptoms, which resolve in a few hours, but vomiting, diarrhoea, abdominal pain, flushing around the neck and face, and a burning sensation in the mouth may occur. Respiratory distress and cardiac problems are rare. Scombrotoxic fish poisoning usually occurs after the consumption of fish such as tuna, mackerel, skipjack, and bonito.
Aflatoxins produced by common moulds in maize and other crops, causing chronic and acute liver disease.
Shellfish which have eaten poisonous plankton, causing paralysis or diarrhoea.
[CDC, 2005b; HPA, 2007c; HPA, 2008; CDC, 2009; HPA, 2009i; HPA, 2009j; HPA, 2009k]
Yersinia enterocolitica
Yersinia enterocolitica
Yersinia enterocolitica is rare. It is a Gram-negative, rod-shaped bacterium that can cause a variety of symptoms:
Infection with Y. enterocolitica occurs most commonly in young children. Common symptoms are watery diarrhoea (which is often bloody), fever, and abdominal pain.
In older children and adults, right-sided abdominal pain and fever may be the predominant symptoms, and can be confused with appendicitis. In a small proportion of cases, complications such as skin rash, joint pains, or spread of bacteria to the bloodstream can occur.
Symptoms typically develop 4–7 days after exposure and can last 1–3 weeks, or longer.
Y. enterocolitica is transmitted through contaminated food and water (organisms can multiply in food at 4°C) and direct contact with infected animals and people. It is often associated with raw pork and pork products.
Parasites
Parasites
Cryptosporidium
Cryptosporidium
Cryptosporidiosis is caused by single-celled parasites of the genus Cryptosporidium.
It is a leading cause of infectious diarrhoea in humans and cattle, and an occasional cause of traveller's diarrhoea. Infection is transmitted by animal-to-human or human-to-human contact, by occupational or recreational exposure to contaminated land or water, or by consuming contaminated water or food.
It causes watery diarrhoea, which can range from mild to severe. Other symptoms can include stomach cramps or pain, dehydration, nausea, vomiting, fever, and weight loss. Symptoms usually last for 1–2 weeks.
In people with impaired immune systems, infection with cryptosporidium may be life-threatening.
Entamoeba histolytica (amoebiasis)
Entamoeba histolytica (amoebiasis)
Entamoebae are single-celled parasites of vertebrates and invertebrates. At least six species of entamoebae are able to colonize the gut of humans, but only one, Entamoeba histolytica, causes disease. There is a morphologically indistinguishable parasite called E. dispar, which is non-pathogenic. Some laboratories will ask for additional samples to carry out tests to distinguish the two species.
Transmission occurs through the ingestion of food or water contaminated with faeces from an infected person or animal. E. histolytica infection in the UK is therefore usually associated with travel abroad.
The disease is often mild (diarrhoea, abdominal pain), but severe disease (amoebic dysentery) can occur. Symptoms of amoebic dysentery include severe abdominal pain, blood and mucus in the faeces, and fever. Rarely, extraintestinal disease occurs when E. histolytica invades the liver (causing an abscess) or occasionally the lungs or the brain.
Giardia
Giardia
Giardiasis is caused by infection with the single-celled parasite, Giardia intestinalis (also known as Giardia lamblia). Giardia organisms colonize the intestinal tracts of vertebrates and invertebrates and cause diarrhoeal disease in humans.
Giardiasis can be transmitted by direct contact with infected animals and humans, or by consumption of water, food, or beverages contaminated by the faeces of infected humans or animals. Many cases are associated with recent foreign travel.
The symptoms of giardiasis include acute and chronic diarrhoea, which can last for 2–6 weeks (occasionally longer), with malabsorption, weight loss, and (in children) failure to thrive. Other symptoms include abdominal pain, anorexia, flatulence, bloating, and nausea; vomiting and fever are uncommon.
Prevalence
How common is it?
About 20% of the UK population develop infectious intestinal disease each year [HPA, 2007a].
Of those infected, only one in six presents to a GP [Wheeler et al, 1999].
Of those who present, only a small proportion will have a stool specimen sent for investigation.
Among people presenting in primary care, viral infections are most common. Rotavirus and Campylobacter are the organisms most commonly identified, with norovirus infections increasing [Jones and Rubin, 2009].
Complications
What are the complications?
The risk of complications from gastroenteritis is greatest at the extremities of life, in people with concurrent chronic disease, and in those who are immunocompromised. Complications include:
Dehydration and electrolyte disturbance
These occur if losses of fluid and electrolytes in the stool are not replaced. Dehydration and electrolyte imbalance from severe diarrhoeal disease can progress to acidosis and circulatory failure, with hypoperfusion of vital organs, renal failure, and eventual death.
Water and electrolyte depletion is variable, depending on the duration of symptoms and the causative pathogen [Farthing et al, 1996].
Dehydration is more likely to occur in young children than in teenagers.
Haemolytic uraemic syndrome (HUS)
HUS is rare, but is one of the more serious complications of acute infectious gastroenteritis. HUS is characterized by acute renal failure, haemolytic anaemia, and thrombocytopenia. It occurs mostly in young children and the elderly [HPA, 2009e].
Reactive complications
These include arthritis, carditis, urticaria, erythema nodosum, conjunctivitis, and Reiter's syndrome (the combination of urethritis, arthritis, and uveitis). They are associated with Salmonella, Campylobacter, Yersinia enterocolitica and Shigella infections.
There are usually no reactive complications associated with viral or parasitic gastroenteritis.
Systemic invasion by Salmonella
This can result in endovascular infections and localized infections in bones, joints, meninges, or the gallbladder.
Toxic megacolon
This is the result of fulminant colitis, and is rare.
Guillain-Barré syndrome
Guillain-Barré syndrome is associated with a number of viruses as well as with several conditions not due to infection. Rarely, it is associated with Campylobacter [Rees et al, 1995].
Malnutrition
Malnutrition can follow some infections, and is a common risk in developing countries [Guerrant et al, 2001].
Intractable diarrhoea
Rarely, diarrhoea can be intractable and require long-term parenteral nutrition or even small-intestinal transplantation [Walker-Smith and Murch, 2003].
Irritable bowel syndrome
A meta-analysis reported that the risk of developing irritable bowel syndrome was increased sevenfold after infectious gastroenteritis [Halvorson et al, 2006].
Acquired secondary lactose intolerance
Secondary or acquired lactose intolerance can occur when the intestine is damaged by gastrointestinal illness, including gastroenteritis [Swagerty et al, 2002].
Reduced absorption of drugs
Gastroenteritis can reduce the absorption of drugs taken for other conditions (for example drugs for epilepsy, diabetes, contraception, malaria prophylaxis, and anticoagulation) [Spira, 2003].
Prognosis
What is the prognosis?
Infectious diarrhoea is usually a mild, self-limiting illness [HPA, 2007a].
In developed countries, dehydration secondary to gastroenteritis can lead to hospital admission, but death is uncommon [World Gastroenterology Organisation, 2008]. Elderly people are at greatest risk of death.
In developing countries, gastroenteritis is a leading cause of death, and can be responsible for the death of as many as 3 million children worldwide each year [Banks and Farthing, 2003].
There is little published evidence on risk factors for poor outcomes from acute gastroenteritis, but experts suggest that the risk factors include [Banks and Farthing, 2003]:
Pre-existing medical conditions, such as immunodeficiency, gastric hypochlorhydria, inflammatory bowel disease, valvular heart disease/prosthetic valves, aortic or ventricular aneurysm, diabetes mellitus, renal impairment, rheumatoid arthritis, and systemic lupus erythematosus.
Certain drug treatments, such as immunosuppressants, systemic corticosteroids, and diuretics.
Diagnosis
Diagnosis of gastroenteritis
Diagnosis
How do I know my patient has it?
Symptoms of gastroenteritis include diarrhoea (loose or watery stools, usually at least three times in 24 hours).
Other symptoms may include:
Sudden onset of vomiting.
Blood or mucus in stool.
Systemic features (for example fever or malaise).
The diagnosis of gastroenteritis is usually made on the basis of clinical symptoms and signs.
Diagnostic investigations are rarely needed, but examination and culture of a stool sample may be necessary to determine the cause.
Basis for recommendation
Basis for recommendation
This information is based on a guideline from the World Health Organization on the treatment of diarrhoea [WHO, 2003].
Differential diagnosis
What else might it be?
Consider an alternative diagnosis if any of the following features are present:
Fever:
Temperature of 38°C or more in children younger than 3 months of age.
Temperature of 39°C or more in children 3 months of age or older.
Shortness of breath or tachypnoea.
Altered conscious state.
Neck stiffness.
Bulging fontanelle in infants.
Non-blanching rash.
Blood and/or mucus in stool.
Bilious (green) vomit.
Severe or localized abdominal pain.
Abdominal distension or rebound tenderness.
The differential diagnosis of acute gastroenteritis includes:
Non-gastrointestinal infections, for example:
Urinary tract infection, pneumonia, otitis media, or systemic infection. In these conditions vomiting is usually more prominent than diarrhoea.
First-time presentation of chronic diarrhoea. Possible causes include:
Gastrointestinal conditions, for example irritable bowel syndrome, ulcerative colitis/Crohn's disease (usually presents with bloody stools), Hirschsprung's enterocolitis, short bowel syndrome, food-sensitive enteropathy (such as lactose intolerance), and coeliac disease. In children, toddler's diarrhoea, or constipation with overflow.
Drugs, for example antibiotics, antimalarials, magnesium-containing antacids, and antimotility drugs; and laxative abuse (the condition normally reverses on withdrawal of the drug).
Endocrinopathy, for example diabetes, hyperthyroidism, congenital adrenal hyperplasia, Addison's disease, and hypoparathyroidism.
Non-enteral infections, for example HIV/AIDS.
Secretory tumours, for example carcinoid tumours, medullary tumour of the thyroid, and vasoactive intestinal peptide-secreting adenomas.
Basis for recommendation
Basis for recommendation
Features suggesting an alternative diagnosis
This recommendation is based on the National Institute for Health and Clinical Excellence (NICE) guideline Diarrhoea and vomiting caused by gastroenteritis: diagnosis, assessment, and management in children younger than 5 years [NICE, 2009].
Differential diagnosis of gastroenteritis
This information is based on expert opinion in a review article [Armon et al, 2001] and a textbook [Seller, 1996].
Management
Management
Scenario: Child: remote presentation: covers the management of children with gastroenteritis who present remotely (for example by telephone).
Scenario: Child: face-to-face presentation: covers the management of children with gastroenteritis during a face-to-face consultation.
Scenario: Adult: covers the management of adults with gastroenteritis.
Scenario: Child: remote presentation
Scenario: Child: remote presentation of gastroenteritis
Remote assessment
How should I remotely assess a child with gastroenteritis?
The following recommendations provide a framework for making decisions. In all cases clinical judgement is needed — if in doubt, use caution or seek advice.
Ensure alternative diagnoses have been considered (see Differential diagnosis).
Document the frequency and consistency of stools, frequency of vomiting, and whether blood or mucus are present in the stool.
Assess possible sources of infection:
Recent contact with someone with acute diarrhoea and/or vomiting.
Exposure to a possible source of enteric infection (for example eating out).
Recent travel abroad.
Check for indicators of dehydration and shock (see NICE criteria for dehydration - remote assessment).
Arrange emergency transfer to hospital if:
Features of shock are described by the parent or carer.
The child has features that might suggest an alternative life-threatening diagnosis (for example the child seems to be very ill, has a non-blanching rash, or has severe breathing difficulty).
Arrange for a face-to-face assessment (this will usually be on the same day, but use clinical judgement) if:
Symptoms suggest an alternative, serious diagnosis (see Differential diagnosis).
The child has a single acute episode of bloody diarrhoea.
Symptoms suggest the child is dehydrated (see NICE criteria for dehydration - remote assessment).
Risk factors are present which indicate an increased risk of dehydration:
Infants younger than 1 year of age, and especially if younger than 6 months.
Infants who were of low birthweight.
Infants who have stopped breastfeeding during their illness.
Children who have passed six or more diarrhoeal stools in the past 24 hours.
Children who have vomited three times or more in the past 24 hours.
The child's social circumstances make assessment over the telephone unreliable.
NICE criteria for dehydration - remote assessment
NICE criteria for dehydration - remote assessment
NICE assessment criteria for dehydration and shock are shown in Table 1.
Table 1. Symptoms and signs of dehydration and shock which can be assessed remotely.| No clinically detectable dehydration | Clinical dehydration | Clinical shock |
|---|---|---|
| Appears well | Appears to be unwell or deteriorating* | — |
| Alert and responsive | Altered responsiveness (for example irritable, lethargic)* | Decreased level of consciousness |
| Normal urine output | Decreased urine output | — |
| Skin colour unchanged | Skin colour unchanged | Pale or mottled skin |
| Warm extremities | Warm extremities | Cold extremities |
Basis for recommendation
Basis for recommendation
These recommendations are based mainly on the National Institute for Health and Clinical Excellence (NICE) guideline Diarrhoea and vomiting caused by gastroenteritis: diagnosis, assessment, and management in children younger than 5 years [NICE, 2009].
The recommendations to assess potential sources of infection and to arrange emergency transfer to hospital if the child has features suggesting a life-threatening diagnosis are based on pragmatic advice and standard practice.
A combined Royal College of Paediatrics and Child Health, Royal College of General Practitioners, and Health Protectection Agency publication The management of acute bloody diarrhoea potentially caused by vero cytotoxin-producing E. coli in children [HPA, 2011] recommends urgent paediatric advice and secondary care assessment is obtained following a child having a single acute episode of bloody diarrhoea. This is due to the risk of possible vero cytotoxin-producing E. coli (VTEC) infection.
There should be a high index of clinical suspicion of VTEC infection in a child who has recently visited an open farm within 21 days, who has been in contact with a known or suspected case of VTEC, or who lives in an area where there is a suspected or confirmed VTEC infection outbreak.
Rehydration advice
What advice should I give about rehydration?
If the child is being managed at home with telephone advice:
Advise continued breastfeeding and other milk feeds.
Encourage fluid intake (but discourage fruit juices and carbonated drinks).
Basis for recommendation
Basis for recommendation
This recommendation is based on the National Institute for Health and Clinical Excellence (NICE) guideline Diarrhoea and vomiting caused by gastroenteritis: diagnosis, assessment, and management in children younger than 5 years [NICE, 2009].
The NICE guideline development group does not recommend giving fruit juices or carbonated drinks to children with diarrhoea because of the high osmolarity of these drinks, which can worsen diarrhoea [National Collaborating Centre for Women's and Children's Health, 2009].
Preventing spread of infection
What advice should I give on preventing spread of infection?
Advise parents, carers, and children that:
Washing hands thoroughly with soap (liquid if possible) in warm running water and careful drying is the best way to prevent the spread of gastroenteritis.
A flush toilet should be used, if possible. If a potty must be used, it should be handled with gloves, the contents disposed of into the toilet, and then washed with hot water and detergent and allowed to dry.
Hands should be washed after going to the toilet and changing nappies, and before preparing, serving, or eating food.
Toilet seats, flush handles, wash-hand basin taps, surfaces, and toilet door handles should be cleaned at least daily with hot water and detergent. Also use disinfectant to clean toilets if available. Use a disposable cloth or one dedicated for toilet use.
Towels and flannels used by infected children should not be shared.
Soiled clothing and bed linen should be washed separately from other clothes at the highest temperature they will tolerate (for example 60°C or higher for linen) after removal of excess faecal matter into the toilet. Soaking in disinfectant is not necessary. Do not fill the machine more than half-full to allow for adequate washing and rinsing.
Children should not attend any school or other childcare facility while they have diarrhoea or vomiting.
Children should not go back to school or other childcare facility until at least 48 hours after the last episode of diarrhoea or vomiting. Public Health authorities will advise if a pathogen is isolated from a child's stool sample (for example Salmonella, Escherichia coli O157): longer periods of exclusion are required in some circumstances.
If cryptosporidiosis is suspected or confirmed, children should not enter swimming pools for 2 weeks after the last episode of diarrhoea.
Basis for recommendation
Basis for recommendation
These recommendations are based on the National Institute for Health and Clinical Excellence (NICE) guideline Diarrhoea and vomiting caused by gastroenteritis: diagnosis, assessment, and management in children younger than 5 years [NICE, 2009], advice from the Public Health Laboratories Service (now covered by the Health Protection Agency) [PHLS Advisory Committee on Gastrointestinal Infections, 2004], and a guideline from the International Scientific Forum for Home Hygiene [IFH Scientific Advisory Board, 2001].
Hand washing
A Cochrane systematic review on hand washing to prevent diarrhoea identified 14 randomized controlled trials of limited quality, of which five were community-based but in low- and middle-income countries [Ejemot et al, 2008]. Eight trials were carried out in high-income countries, but were institution-based. Only trials that adjusted for cluster randomization (the allocation of groups rather than individuals in the randomization process) were included.
Interventions which encouraged hand washing resulted in a 39% reduction in diarrhoeal episodes in children in institutions in high-income countries in two trials (incidence rate ratio [IRR] 0.61, 95% CI 0.40 to 0.92). In children living in the community in low- or middle-income countries, there was a 32% reduction in diarrhoeal episodes in four trials (IRR 0.68, 95% CI 0.52 to 0.90).
Swimming
The recommendation to avoid swimming pools for 2 weeks after the first normal stool if cryptosporidiosis is suspected or confirmed is based on the fact that oocysts resist standard chlorination, and can continue to be shed following cessation of diarrhoea [PHLS Advisory Committee on Gastrointestinal Infections, 2004].
Follow-up advice
What advice should I give about follow up?
If the child is being managed at home with telephone advice, reassure the parents or carers that:
The usual duration of diarrhoea is 5–7 days, and in most children it stops within 2 weeks.
The usual duration of vomiting is 1 or 2 days, and in most children it stops within 3 days.
They should seek advice from a healthcare professional if their child's symptoms do not resolve within these time frames.
Provide a 'safety net', advising the parents or carers when review is necessary (for example if symptoms of dehydration develop, or the child has persistent vomiting), and how to access further medical help.
Advise the parents or carers to seek immediate medical help if red flag symptoms are identified (for example the child appears unwell or is deteriorating, or is irritable, lethargic, or less responsive).
Basis for recommendation
Basis for recommendation
This recommendation is based on the National Institute for Health and Clinical Excellence (NICE) guideline Diarrhoea and vomiting caused by gastroenteritis: diagnosis, assessment, and management in children younger than 5 years [NICE, 2009].
Scenario: Child: face-to-face presentation
Scenario: Child: face-to-face presentation of gastroenteritis
Face-to-face assessment
How should I assess a child with gastroenteritis who presents face-to-face?
Consider alternative diagnoses.
Document the frequency and consistency of stools, frequency of vomiting, and whether blood or mucus are present in the stool.
Assess possible sources of infection:
Recent contact with someone with acute diarrhoea and/or vomiting.
Exposure to a possible source of enteric infection (for example eating out).
Recent travel abroad.
Assess for dehydration and shock (see NICE criteria for dehydration - face-to-face assessment).
NICE criteria for dehydration - face-to-face assessment
NICE criteria for dehydration - face-to-face assessment
NICE assessment criteria for dehydration and shock are shown in Table 1.
Table 1. Symptoms and signs of dehydration and shock.| Symptoms and signs | No clinically detectable dehydration | Clinical dehydration | Clinical shock |
|---|---|---|---|
| Symptoms (remote and face-to-face assessments) | Appears well | Appears to be unwell or deteriorating* | — |
| Alert and responsive | Altered responsiveness (for example irritable, lethargic)* | Decreased level of consciousness | |
| Normal urine output | Decreased urine output | — | |
| Skin colour unchanged | Skin colour unchanged | Pale or mottled skin | |
| Warm extremities | Warm extremities | Cold extremities | |
| Signs (face-to-face assessments) | Alert and responsive | Altered responsiveness (for example irritable, lethargic)* | Decreased level of consciousness |
| Skin colour unchanged | Skin colour unchanged | Pale or mottled skin | |
| Warm extremities | Warm extremities | Cold extremities | |
| Eyes not sunken | Sunken eyes* | — | |
| Moist mucous membranes (except after a drink) | Dry mucous membranes (except for mouth breathing) | — | |
| Normal heart rate | Tachycardia* | Tachycardia | |
| Normal breathing pattern | Tachypnoea* | Tachypnoea | |
| Normal peripheral pulses | Normal peripheral pulses | Weak peripheral pulses | |
| Normal capillary refill time | Normal capillary refill time | Prolonged capillary refill time | |
| Normal skin turgor | Reduced skin turgor* | — | |
| Normal blood pressure | Normal blood pressure | Hypotension (decompensated shock) | |
Basis for recommendation
Basis for recommendation
These recommendations are based on the National Institute for Health and Clinical Excellence (NICE) guideline Diarrhoea and vomiting caused by gastroenteritis: diagnosis, assessment, and management in children younger than 5 years [NICE, 2009].
Hospital admission
When should I admit a child with gastroenteritis?
Arrange emergency transfer to secondary care for children with symptoms or signs suggesting shock (see NICE criteria for dehydration - face-to-face assessment).
Consider further assessment in secondary care in the following circumstances:
Signs consistent with dehydration.
Altered responsiveness, for example, irritable or lethargic.
A single acute episode of bloody diarrhoea.
Young age (less than 6 months of age or less than 8 kg body weight).
History of premature birth, chronic medical conditions (for example severe cardiac or renal disease), or concurrent illness.
Fever 38°C or more for infants younger than 3 months of age, or more than 39°C for children 3–36 months of age.
High output diarrhoea including frequent and substantial volumes.
Persistent vomiting or persistent fever.
Suboptimal response to oral rehydration therapy.
No improvement in 48 hours, or overall condition that is worsening.
Decide whether monitoring the response to rehydration therapy can be carried out safely in the home setting and if so under what level of supervision (for example general practitioner, community children's nurse). If there are concerns about the parent's ability to monitor their child's condition and to provide appropriate care, consider admission to hospital.
Basis for recommendation
Basis for recommendation
Shock
This recommendation is based on the National Institute for Health and Clinical Excellence (NICE) guideline Diarrhoea and vomiting caused by gastroenteritis: diagnosis, assessment, and management in children younger than 5 years [NICE, 2009].
Consideration of admission
This recommendation is based on suggested indications for in-patient care from an expert consensus guideline [World Gastroenterology Organisation, 2008].
Following a outbreak of E. coli 0157 at an open farm in the UK, the Health Protection Agency (HPA) has reminded prescribers that children with bloody diarrhoea should be admitted to hospital, to confirm the diagnosis and prevent the spread of infection to others in the household [Independent Investigation Committee, 2010]. This is further supported by a combined Royal College of Paediatrics and Child Health, Royal College of General Practitioners, and Health Protection Agency publication The management of acute bloody diarrhoea potentially caused by vero cytotoxin-producing E. coli in children [HPA, 2011]. This document recommends urgent paediatric advice and secondary care assessment is obtained following a child having a single acute episode of bloody diarrhoea due to the risk of possible vero cytotoxin-producing E. coli (VTEC) infection, so that a prompt diagnosis is made, management is started, and appropriate infection control measures are taken.
There should be a high index of clinical suspicion of VTEC infection in a child who has recently visited an open farm within 21 days, who has been in contact with a known or suspected case of VTEC, or who lives in an area where there is a suspected or confirmed VTEC infection outbreak [HPA, 2011].
Taking into account social factors when deciding whether to admit to hospital is discussed in a UK guideline commissioned on behalf of NICE [National Collaborating Centre for Women's and Children's Health, 2009].
Stool sample analysis
When should I send a stool sample for analysis?
When to request a stool sample
Perform stool microbiological investigations if:
There is blood and/or mucus in the stool.
The child is immunocompromised.
Consider performing stool microbiological investigations if:
The child has recently been abroad to anywhere other than Western Europe, North America, Australia or New Zealand, or
The diarrhoea has not improved by day 7, or
There is uncertainty about the diagnosis of gastroenteritis.
How to send a stool sample to the laboratory
Send a single specimen (1 mL, or a pea-sized sample, is the minimum needed for routine investigation) for stool culture and sensitivity.
If the child has recently travelled abroad to anywhere other than Western Europe, North America, Australia or New Zealand, also request tests for ova, cysts, and parasites.
If diarrhoea is recurrent, and parasitic infection is suspected, send three specimens (5 mL each) 2–3 days apart.
Ensure the following details are stated on the request form:
Clinical features (for example systemic illness, fever, bloody stool, abdominal pain; and onset, duration, and recurrence of symptoms).
History of immunosuppression.
Food intake (for example barbecue, restaurant, types of food eaten).
Recent foreign travel (state the country visited).
Recent antibiotic or proton pump inhibitor treatment, or recent hospital admission.
Exposure to untreated water.
Contact with other affected individuals or outbreaks.
For more information on how to advise parents to collect a stool sample, see Collection of stool samples.
Collection of stool samples
Collection of stool samples
Advise the parent or carer:
Not to allow urine to mix with the stool sample, if possible.
To use a potty or, if the child uses the toilet, place a wide-mouth container (for example a potty or empty plastic food container) in the bowl, or put clean newspaper or plastic wrap over the toilet seat opening.
That the child should pass stool on to the potty, plastic container, newspaper, or plastic wrap.
Using the supplied collecting device, to place small scoopfuls of stool from areas which appear bloody, slimy, or watery into the tube. Do not overfill. Try not to spill stool on the outside of the tube.
To replace the collection tube lid and screw it on tightly.
To dispose of stool remaining in the potty, plastic container, or newspaper down the toilet. Clean the potty with hot soapy water. Wrap the plastic container, newspaper, or plastic wrap in newspaper, and dispose of it in normal refuse, in a plastic bag.
To label the collection tube with the child's name, date of birth, and the date of collection.
To place the collection tube in the plastic bag attached to the specimen request form.
To wash their hands thoroughly in hot, running water with soap.
To deliver the sample to the surgery or laboratory as soon as possible.
Basis for recommendation
Basis for recommendation
These recommendations are based on the National Institute for Health and Clinical Excellence (NICE) guideline Diarrhoea and vomiting caused by gastroenteritis: diagnosis, assessment, and management in children younger than 5 years [NICE, 2009], and advice from the Health Protection Agency [HPA, 2007a].
Pathogens routinely looked for during microbiological examination of a stool sample are Campylobacter, Cryptosporidium, Escherichia coli 0157, Salmonella, and Shigella. Testing for other pathogens may be carried out depending on the clinical history [HPA, 2007a].
Rehydration advice
What advice should I give about rehydration?
In children with gastroenteritis, but without clinical dehydration, advise the parents to:
Continue with the usual feeds, including breastfeeding and other milk feeds.
Encourage fluid intake.
Discourage the drinking of fruit juices and carbonated drinks.
Offer oral rehydration salt (ORS) solution as supplemental fluid to those at increased risk of dehydration.
In children with clinical symptoms or signs of dehydration who can be managed at home, advise the parents to:
Use ORS solution to rehydrate:
For children 5 years of age or younger: give 50 mL/kg body weight for fluid deficit replacement over 4 hours, as well as maintenance volume of ORS solution (breastfeeding can continue, but do not routinely give oral fluids other than ORS solution). See Additional information for an example of how to calculate a child's maintenance fluid volume requirement.
For children older than 5 years of age: give 200 mL ORS solution after each loose stool (in addition to the child's normal fluid intake).
Give the ORS solution frequently and in small amounts.
Consider supplementation with the child's usual fluids if they refuse to take sufficient quantities of ORS solution and do not have red flag symptoms and signs (child appears unwell or is deteriorating, altered responsiveness, sunken eyes, tachycardia, tachypnoea, decreased skin turgor).
Avoid giving solid food.
Monitor the response to oral rehydration therapy by regular clinical assessment.
Seek urgent medical advice if the child is unable to drink, or vomits persistently.
After rehydration, advise the parents to:
Encourage the child to drink plenty of their usual fluids, including milk feeds if these were stopped.
Avoid giving the child fruit juices and carbonated drinks until the diarrhoea has stopped.
Reintroduce the child's usual diet.
Give children at increased risk of dehydration recurring 5 mL of ORS solution per kilogram body weight after each large watery stool.
For more information on which children are at increased risk of dehydration, see Additional information.
Additional information
Additional information
Children at increased risk of dehydration
Children at increased risk of dehydration are those:
Younger than 1 year of age, particularly younger than 6 months.
Infants who were of low birthweight.
Who have passed more than five diarrhoeal stools in the previous 24 hours.
Who have vomited more than twice in the previous 24 hours.
Who have not been offered, or have not been able to tolerate, supplementary fluids before presentation.
Infants who have stopped breastfeeding during their illness.
With signs of malnutrition.
Maintenance fluid volume requirements
Maintenance fluid volume requirements are based on body weight:
For a child who weighs 0–10 kg, the volume of fluid required per day to maintain hydration is 100 mL/kg per day.
For example if the child weighs 5 kg, the maintenance fluid volume is 500 mL/day.
For a child who weighs 10–20 kg, the volume of fluid required per day to maintain hydration is 1000 mL plus 50 mL/kg for each kg over 10 kg.
For example if the child weighs 15 kg, the maintenance fluid volume is 1250 mL/day.
For a child who weighs more than 20 kg, the volume of fluid required per day to maintain hydration is 1500 mL plus 20 mL/kg for each kg over 20 kg.
For example if the child weighs 25 kg, the maintenance fluid volume is 1600 mL/day.
[National Collaborating Centre for Women's and Children's Health, 2009]
Basis for recommendation
Basis for recommendation
These recommendations are based on the National Institute for Health and Clinical Excellence (NICE) guideline Diarrhoea and vomiting caused by gastroenteritis: diagnosis, assessment, and management in children younger than 5 years [NICE, 2009].
The recommendation on the amount of ORS solution to give to a child older than 5 years of age is based on the British National Formulary [BNF 57, 2009].
The NICE guideline development group does not recommend giving fruit juices or carbonated drinks to children with diarrhoea because of the high osmolarity of these drinks, which can worsen diarrhoea [National Collaborating Centre for Women's and Children's Health, 2009].
Preventing spread of infection
What advice should I give on preventing spread of infection?
Advise parents, carers, and children that:
Washing hands thoroughly with soap (liquid if possible) in warm running water and careful drying is the best way to prevent the spread of gastroenteritis.
A flush toilet should be used, if possible. If a potty must be used, it should be handled with gloves, the contents disposed of into the toilet, and then washed with hot water and detergent and allowed to dry.
Hands should be washed after going to the toilet and changing nappies, and before preparing, serving, or eating food.
Toilet seats, flush handles, wash-hand basin taps, surfaces, and toilet door handles should be cleaned at least daily with hot water and detergent. Also use disinfectant to clean toilets if available. Use a disposable cloth or one dedicated for toilet use.
Towels and flannels used by infected children should not be shared.
Soiled clothing and bed linen should be washed separately from other clothes at the highest temperature they will tolerate (for example 60°C or higher for linen) after removal of excess faecal matter into the toilet. Soaking in disinfectant is not necessary. Do not fill the machine more than half-full to allow for adequate washing and rinsing.
Children should not attend any school or other childcare facility while they have diarrhoea or vomiting.
Children should not go back to school or other childcare facility until at least 48 hours after the last episode of diarrhoea or vomiting. Public Health authorities will advise if a pathogen is isolated from a child's stool sample (for example Salmonella, Escherichia coli O157): longer periods of exclusion are required in some circumstances.
If cryptosporidiosis is suspected or confirmed, children should not enter swimming pools for 2 weeks after the last episode of diarrhoea.
Basis for recommendation
Basis for recommendation
These recommendations are based on the National Institute for Health and Clinical Excellence (NICE) guideline Diarrhoea and vomiting caused by gastroenteritis: diagnosis, assessment, and management in children younger than 5 years [NICE, 2009], advice from the Public Health Laboratories Service (now covered by the Health Protection Agency) [PHLS Advisory Committee on Gastrointestinal Infections, 2004], and a guideline from the International Scientific Forum for Home Hygiene [IFH Scientific Advisory Board, 2001].
Hand washing
A Cochrane systematic review on hand washing to prevent diarrhoea identified 14 randomized controlled trials of limited quality, of which five were community-based but in low- and middle-income countries [Ejemot et al, 2008]. Eight trials were carried out in high-income countries, but were institution-based. Only trials that adjusted for cluster randomization (the allocation of groups rather than individuals in the randomization process) were included.
Interventions which encouraged hand washing resulted in a 39% reduction in diarrhoeal episodes in children in institutions in high-income countries in two trials (incidence rate ratio [IRR] 0.61, 95% CI 0.40 to 0.92). In children living in the community in low- or middle-income countries, there was a 32% reduction in diarrhoeal episodes in four trials (IRR 0.68, 95% CI 0.52 to 0.90).
Swimming
The recommendation to avoid swimming pools for 2 weeks after the first normal stool if cryptosporidiosis is suspected or confirmed is based on the fact that oocysts resist standard chlorination, and can continue to be shed following cessation of diarrhoea [PHLS Advisory Committee on Gastrointestinal Infections, 2004].
Drug treatment
Should I prescribe drug treatment?
Antidiarrhoeal medications are not recommended for children with gastroenteritis.
Anti-emetics are not recommended for children with vomiting associated with gastroenteritis.
Do not routinely give antibiotics to children with gastroenteritis.
Seek specialist advice regarding antibiotic treatment when:
The child has recently been abroad.
Stool culture reveals a causative organism.
Following specialist advice, antibiotics should be considered for those children:
With suspected or confirmed septicaemia.
With extra-intestinal spread of bacterial infection.
Who are younger than 6 months of age, with Salmonella gastroenteritis.
Who are malnourished or immunocompromised, with Salmonella gastroenteritis.
With Clostridium difficile-associated pseudomembranous enterocolitis, giardiasis, dysenteric shigellosis, dysenteric amoebiasis, or cholera.
Probiotics are not recommended for the management of children with gastroenteritis.
Basis for recommendation
Basis for recommendation
These recommendations are based on the National Institute for Health and Clinical Excellence (NICE) guideline Diarrhoea and vomiting caused by gastroenteritis: diagnosis, assessment, and management in children younger than 5 years [NICE, 2009] and the associated evidence summary [National Collaborating Centre for Women's and Children's Health, 2009].
Antidiarrhoeal drugs
NICE found no evidence to support the use of kaolin in children with diarrhoea. Although there was some evidence from one small study to suggest a beneficial effect of charcoal, the Guideline Development Group (GDG) considered that young children would find this unpalatable.
Although there is good evidence from a systematic review that loperamide is effective at reducing the frequency and duration of diarrhoea in children, the GDG did not recommend its use because it is not licensed for use in young children, and it is associated with serious adverse effects (defined as presence of ileus, lethargy, or death).
Anti-emetics
Evidence from randomized controlled trials suggests that oral ondansetron increases the success rate with oral rehydration therapy. However, the GDG was concerned that ondansetron might worsen diarrhoea. Weak evidence does not support the use of other anti-emetics. The GDG concluded that administration of anti-emetics in children with gastroenteritis could not currently be recommended.
Probiotics
There is evidence on the use of probiotics, but with such variation between studies that the GDG was unable to recommend them.
Empirical antibiotics
Weak evidence from randomized controlled trials is conflicting, but suggests that empirical antibiotics may reduce the duration of diarrhoea. However, the GDG did not consider these studies to be relevant to the current UK setting.
The GDG noted that the spectrum of pathogens that are commonly responsible for gastroenteritis in children in the UK is such that empirical antibiotic treatment is unlikely to be effective.
Antibiotics when stool culture is positive
NICE recommends antibiotic treatment for all children with Salmonella gastroenteritis who are younger than 6 months of age or who are malnourished or immunocompromised. NICE also recommends treatment for children with Clostridium difficile-associated pseudomembranous enterocolitis, giardiasis, dysenteric shigellosis, dysenteric amoebiasis, or cholera.
Because of the potential complications of severe infection and risks associated with antibiotic treatment, CKS recommends seeking specialist advice regarding antibiotic treatment when the child's stool culture is positive.
Traveller's diarrhoea
NICE found no evidence on the treatment of traveller's diarrhoea in children. However, in adults with traveller's diarrhoea, there is some evidence of benefit from antibiotic treatment.
The GDG agreed that consideration should be given to seeking specialist advice regarding antibiotic treatment in children presenting with acute diarrhoea shortly after returning from overseas travel.
Confirmed microbiological cause
How do I manage a child with gastroenteritis that is due to a confirmed cause?
Seek specialist advice regarding antibiotic treatment when stool culture reveals a causative organism.
Provide information to parents and carers.
A range of information sheets for specific causative organisms can be found at www.gutfeelings.org.uk, including:
Verocytotoxin-producing Escherichia coli (VTEC) O157 (pdf)
Basis for recommendation
Basis for recommendation
NICE recommends antibiotic treatment for all children with Salmonella gastroenteritis who are younger than 6 months of age or who are malnourished or immunocompromised. NICE also recommends treatment for children with Clostridium difficile-associated pseudomembranous enterocolitis, giardiasis, dysenteric shigellosis, dysenteric amoebiasis, or cholera [NICE, 2009].
Because of the potential complications of severe infection and risks associated with antibiotic treatment, CKS recommends seeking specialist advice regarding antibiotic treatment when the child's stool culture is positive.
Follow-up advice
What advice should I give about follow up?
Reassure the parents or carers that:
The usual duration of diarrhoea is 5–7 days, and in most children it stops within 2 weeks.
The usual duration of vomiting is 1 or 2 days, and in most children it stops within 3 days.
They should seek advice from a healthcare professional if their child's symptoms do not resolve within these time frames.
Provide a 'safety net', advising the parents or carers when review is necessary (for example if symptoms of dehydration develop, or the child has persistent vomiting), and how to access further medical help.
Advise the parents or carers to seek immediate medical help if red flag features are identified (for example the child appears unwell or is deteriorating, or is irritable, lethargic, or less responsive).
Basis for recommendation
Basis for recommendation
These recommendations are based on the National Institute for Health and Clinical Excellence (NICE) guideline Diarrhoea and vomiting caused by gastroenteritis: diagnosis, assessment, and management in children younger than 5 years [NICE, 2009].
Notifying public health authorities
When should I notify public health authorities?
Notify the Local Authority Proper Officer (in England and Wales, the local Consultant in Communicable Disease Control) if a case of any of the following is suspected:
Cholera.
Bloody diarrhoea presumed to be due to gastroenteritis.
Food poisoning (organisms that can be implicated in food poisoning include Campylobacter, Escherichia coli O157:H7, Salmonella, Shigella, Giardia, Yersinia enterolytica, Entamoeba histolytica, and norovirus).
Haemolytic uraemic syndrome (HUS).
Complete an official Formal Notification Certificate (from a pad supplied locally) immediately on diagnosis of a suspected notifiable disease and return it to where the pad was obtained within 3 days (this could be the Local Authority, Primary Care Trust, or Health Protection Unit).
If urgent notification is needed (such as for suspected cholera, infectious bloody diarrhoea, haemolytic uraemic syndrome, clusters or outbreaks of food poisoning) telephone the local Health Protection Unit with the details. A Formal Notification Certificate must still be sent within 3 days.
Notify and act on the advice of the public health authorities if an outbreak of gastroenteritis is suspected.
Contact details for Health Protection Units in England can be found through the Local and Regional Services page on the Health Protection Agency website www.hpa.org.uk and for health protection teams for Wales on the National Public Health Service for Wales website www.wales.nhs.uk.
The full list of notifiable diseases can be found on the Health Protection Agency website at www.hpa.org.uk.
Basis for recommendation
Basis for recommendation
Which diseases to notify
This recommendation is based on the 1988 Public Health (Infectious Diseases) Regulations [DH, 2010].
How to notify
The recommendation on what action to take in the event of a suspected diagnosis of a notifiable disease is based on expert advice from the Health Protection Agency and the Department of Health [HPA, 2010; HPA, 2009a; DH, 2010].
The recommendation on what action to take if an outbreak is suspected is based on the National Institute for Health and Clinical Excellence (NICE) guideline Diarrhoea and vomiting caused by gastroenteritis: diagnosis, assessment, and management in children younger than 5 years [NICE, 2009].
The definition of who fulfils the role of the Proper Officer is based on guidelines from the British Society for the Study of Infection [Farthing et al, 1996].
Scenario: Adult
Scenario: Adult gastroenteritis
Assessment
How should I assess an adult with gastroenteritis?
Assess the severity of the illness. Ask about:
Frequency and consistency of stools.
The presence of blood in stools.
Frequency of vomiting.
Ability to eat and drink.
Perform an appropriate examination.
Check temperature, blood pressure, and heart and and respiratory rates.
Assess for abdominal tenderness.
Assess for features of dehydration.
Investigate potential causes or contributing factors by asking about:
Recent contact with someone with acute diarrhoea and/or vomiting.
Exposure to a known source of enteric infection (possibly contaminated water or food).
Recent travel abroad.
Recent antibiotics or hospital admission within the last 8 weeks — suspect infection with Clostridium difficile.
Use of proton pump inhibitors (reduction in stomach acid reduces resistance to infective organisms).
Assess personal risk factors:
Age — elderly people are at greater risk of serious dehydration and complications.
Pregnant women are at greater risk of dehydration and complications, for example following Salmonella infection.
Those who are immunocompromised or have co-existing medical conditions (for example renal impairment, inflammatory bowel disease, diabetes mellitus, connective tissue disorders) are at greater risk of more severe disease and complications.
Review medications — certain medications may be affected by severe diarrhoea (for example warfarin, anticonvulsants, and the oral contraceptive pill), or can exacerbate dehydration and renal failure (for example diuretics, angiotensin-converting enzyme inhibitors).
Clinical features of dehydration
Clinical features of dehydration
Mild dehydration
Lassitude.
Anorexia, nausea.
Light headedness.
Postural hypotension.
Usually no signs.
Moderate dehydration
Apathy/tiredness.
Dizziness.
Muscle cramps.
Pinched face.
Dry tongue or sunken eyes.
Reduced skin elasticity.
Postural hypotension (systolic blood pressure > 90 mmHg).
Tachycardia.
Oliguria.
Severe dehydration
Profound apathy.
Weakness.
Confusion, leading to coma.
Shock.
Tachycardia.
Marked peripheral vasoconstriction.
Systolic blood pressure < 90 mmHg.
Oliguria or anuria.
Basis for recommendation
Basis for recommendation
This recommendation is based on expert opinion in a guideline from the World Gastroenterology Organisation [World Gastroenterology Organisation, 2008] and a pragmatic approach to what is considered standard practice.
Hospital admission
When should I admit an adult with gastroenteritis?
Arrange emergency admission to hospital if:
The person is vomiting and unable to retain oral fluids.
They have features of shock or severe dehydration.
Other factors influencing admission (clinical judgement should be used) include:
Recent foreign travel.
Older age (people 60 years of age or older are more at risk of complications).
Home circumstances and level of support.
Fever.
Bloody diarrhoea.
Abdominal pain and tenderness.
Faecal incontinence.
Diarrhoea lasting more than 10 days.
Increased risk of poor outcome, for example:
Coexisting medical conditions — immunodeficiency, lack of stomach acid, inflammatory bowel disease, valvular heart disease, diabetes mellitus, renal impairment, rheumatoid disease, systemic lupus erythematosus.
Drugs — immunosuppressants or systemic steroids, proton pump inhibitors, H2-receptor antagonists, simple antacids, angiotensin-converting enzyme inhibitors, diuretics.
Basis for recommendation
Basis for recommendation
This recommendation is based on an expert-consensus guideline from the British Society for the Study of Infection [Farthing et al, 1996].
Stool sample analysis
When should I send a stool sample for analysis?
When to send a stool sample for culture
Stool cultures are usually not necessary for most adults who present with acute, watery diarrhoea.
Send a stool specimen if:
The person is systemically unwell.
There is blood or pus in the stool.
Diarrhoea occurs after foreign travel to anywhere other than Western Europe, North America, Australia or New Zealand.
Diarrhoea is persistent and giardiasis is suspected.
Reassurance is required, as the diagnosis of infection may exclude other pathologies.
The person has recently received antibiotics or been in hospital.
The person is immunocompromised.
Seek advice from the local health protection unit in the following circumstances, as samples may be required:
Suspected public health hazard, for example diarrhoea in food handlers, healthcare workers, elderly residents in care homes, or in people in other high risk situations.
Outbreaks of diarrhoea in the family or community, when isolating the organism may help pinpoint the source of the outbreak.
Contacts of people infected with certain organisms, for example Escherichia coli O157, where there may be serious clinical sequelae to an infection.
How to send a stool sample to the laboratory
Send a single specimen (1 mL, or a pea-sized sample, is the minimum needed for routine investigation) for culture and sensitivity.
If the person has recently travelled abroad to anywhere other than Western Europe, North America, Australia or New Zealand, also request tests for ova, cysts, and parasites.
If diarrhoea is recurrent, and parasitic infection is suspected, send three specimens (5 mL each) 2–3 days apart, as ova, cysts, and parasites are shed intermittently.
Ensure the following details are stated on the request form:
Clinical features (for example systemic illness, fever, bloody stool, abdominal pain; and onset, duration, and recurrence of symptoms).
History of immunosuppression.
Food intake (for example barbecue, restaurant, types of food eaten).
Recent foreign travel — state which country.
Recent antibiotic or proton pump inhibitor, or hospital admission in the last 8 weeks.
Exposure to untreated water, for example drinking water or whilst swimming.
Contact with other affected individuals or outbreaks.
For more information on how to advise the person to take a stool sample, see Collection of stool samples.
Collection of stool samples
Collection of stool samples
Advise the person:
Not to allow urine to mix with the stool sample.
To place a wide-mouth container (for example a potty, if available, or empty plastic food container) in the bowl, or put clean newspaper or plastic wrap over the toilet seat opening.
To pass stool on to the potty, plastic container, newspaper, or plastic wrap.
Using the supplied collecting device, to place small scoopfuls of stool from areas which appear bloody, slimy, or watery into the tube. Do not overfill. Try not to spill stool on the outside of the tube.
To replace the collection tube lid and screw it on tightly.
To dispose of stool remaining in the potty, plastic container, or newspaper down the toilet. Clean the potty with hot soapy water. Wrap the plastic container, newspaper, or plastic wrap in newspaper and dispose of it in normal refuse, in a plastic bag.
To label the collection tube with their name, date of birth, and the date of collection.
To place the collection tube in the plastic bag attached to the specimen request form.
To wash their hands thoroughly in hot, running water with soap.
To deliver the sample to the surgery or laboratory as soon as possible.
Basis for recommendation
Basis for recommendation
These recommendations are based on guidelines from the Health Protection Agency [HPA, 2007a] and the World Gastroenterology Association [World Gastroenterology Organisation, 2008].
Pathogens routinely looked for during microbiological examination of a stool sample are Campylobacter, Cryptosporidium, E. coli 0157, Salmonella, and Shigella. Testing for other pathogens may be carried out depending on the clinical history [HPA, 2007a].
Rehydration advice
What advice should I give about rehydration?
In most otherwise healthy adults, encouraging fluid intake (especially if supplemented with fruit juice and soups) will be sufficient.
In adults who are at increased risk of a poor outcome (for example people who are 60 years of age or older, frail, or with comorbidities with which dehydration, hypovolaemia, or haemoconcentration would be a problem, such as cardiovascular disease or thrombotic tendencies), consider supplementing fluid intake with oral rehydration salt solution.
Basis for recommendation
Basis for recommendation
There is little evidence on the use of oral rehydration salt (ORS) solution in adults in developed countries. Evidence is mainly from studies of children in developing countries [Banks and Farthing, 2003].
Drinking standard fluids
An expert-consensus guideline [World Gastroenterology Organisation, 2008] states that in adults able to maintain their fluid intake, ORS solution does not provide any benefits in terms of reducing the duration of diarrhoea or the number of stools. The advice to drink fruit juices and soups is based on expert opinion that they help maintain fluid and electrolyte balance [Wingate et al, 2001; Banks and Farthing, 2003; Farthing, 2003].
Use of oral rehydration salt solution
Expert opinion suggests ORS solution as a treatment option in people who are frail or very elderly [Wingate et al, 2001].
Dietary advice
What advice should I give about diet?
Consumption of solid food should be guided by appetite.
Advise the person to eat small, light meals and avoid fatty, spicy, or heavy food.
Basis for recommendation
Basis for recommendation
There is little evidence on fasting or dieting for the treatment of acute diarrhoea [Wingate et al, 2001]. This recommendation is based on an expert-consensus guideline [World Gastroenterology Organisation, 2008] and expert opinion in a review [Wingate et al, 2001].
The role of diet in acute diarrhoea is controversial. Some experts believe that eating can stimulate defecation, and avoiding large meals may reduce the gastrocolic response. Others suggest that solutes from food may have a similar beneficial effect to the solutes in oral rehydration solutions [Wingate et al, 2001]. Therefore food intake is recommended if the person wishes to eat, but small, light meals are recommended.
Preventing spread of infection
What advice should I give on preventing spread of infection?
Hands should be washed thoroughly with (preferably liquid) soap in warm running water and dried after going to the toilet, changing babies' nappies, and before preparing or serving food or eating meals.
Towels and flannels should not be shared.
A flush toilet should be used if possible. If a commode or bedpan must be used, it should be handled with gloves, the contents disposed of into the toilet, and the container then washed with hot water and detergent and allowed to dry.
Soiled clothing and bed linen should be washed separately from other clothes at the highest temperature they will tolerate (for example 60°C or higher for linen) after removal of excess faecal matter into the toilet. Soaking in disinfectant is not necessary. Do not fill the machine more than half-full to allow for adequate washing and rinsing.
Toilet seats, flush handles, wash-hand basin taps, surfaces, and toilet door handles should be cleaned at least daily with hot water and detergent. Also use disinfectant to clean toilets if available. Use a disposable cloth or one dedicated for toilet use.
Advise exclusion from work or other institutional settings until at least 48 hours after the person is free from diarrhoea and vomiting. Public health authorities will advise if a pathogen is isolated from the person's stool sample (for example Salmonella, Escherichia coli O157): longer periods of exclusion are required in some circumstances.
If cryptosporidiosis is suspected or confirmed, avoid entering swimming pools for 2 weeks after the last episode of diarrhoea.
Basis for recommendation
Basis for recommendation
This recommendation is based on advice from the Public Health Laboratories Service (now covered by the Health Protection Agency) [PHLS Advisory Committee on Gastrointestinal Infections, 2004] and a guideline from the International Scientific Forum for Home Hygiene [IFH Scientific Advisory Board, 2001].
Swimming
The recommendation to avoid swimming pools for 2 weeks after the first normal stool if cryptosporidiosis is suspected or confirmed is based on the fact that oocysts resist standard chlorination, and can continue to be shed following cessation of diarrhoea [PHLS Advisory Committee on Gastrointestinal Infections, 2004].
Drug treatment
When should I prescribe drug treatment?
Antidiarrhoeal drugs are not usually necessary for the management of gastroenteritis.
Antimotility drugs may be useful for symptomatic control in adults with mild-to-moderate diarrhoea, for example if quicker resolution of diarrhoea would enable the person to continue essential activities.
If required, loperamide is the antimotility drug of choice.
Avoid antimotility drugs if there is blood and/or mucus in the stools, or high fever (indicating dysentery).
Antibiotics are not recommended for adults with acute diarrhoea of unknown pathology.
Antibiotics may be appropriate when gastroenteritis is due to a known microbiological cause (see Confirmed microbiological pathogen).
Anti-emetics are not usually necessary for the primary care management of gastroenteritis.
Anti-emetics (such as metoclopramide 10 mg intramuscularly) can be helpful in adults if the person is vomiting severely.
Basis for recommendation
Basis for recommendation
Antidiarrhoeal drugs
Limited evidence from randomized controlled trials suggests that loperamide (flexible dose according to loose bowel movements) may reduce diarrhoea and shorten its duration by up to 24 hours.
Loperamide is the preferred antimotility drug because it has a better adverse-effect profile and there is more evidence for its efficacy.
Antimotility drugs such as codeine, and diphenoxylate with atropine, have more adverse effects affecting the central nervous system than loperamide, which acts peripherally.
Bismuth subsalicylate (Pepto-bismol®) can alleviate symptoms of diarrhoea, nausea, and abdominal pain in traveller's diarrhoea; however, evidence suggests that loperamide is more effective.
Antibiotics
Empirical antibiotics are not generally helpful for acute gastroenteritis managed in primary care. Limited evidence shows that they have minimal benefits, there is a risk of serious adverse effects, and their use promotes the development of resistant bacteria.
In people with traveller's diarrhoea, evidence from a Cochrane systematic review suggests that empirical antibiotic treatment is associated with a reduction in the duration and severity of diarrhoea, but a higher incidence of adverse effects.
In people who present with dysentery, infection is likely to be due to bacterial or protozoal infection (such as Campylobacter, Clostridium difficile, Entamoeba histolytica, Escherichia coli, Salmonella, or Shigella).
Anti-emetics
There is limited evidence that anti-emetics are effective in terms of controlling vomiting, but evidence is inconsistent for clinical benefits such as reducing the need for intravenous rehydration. Nausea and vomiting often improve after adequate rehydration.
Confirmed microbiological pathogen
Confirmed microbiological pathogen
Amoebiasis
How should I treat gastroenteritis caused by Entamoeba histolytica?
Seek advice from the local microbiologist regarding antibiotic management.
Antibiotic treatment is usually recommended for all people with amoebiasis.
The antibiotic of choice is metronidazole, followed by a 10-day course of diloxanide.
Tinidazole is an alternative to metronidazole.
For more information on prescribing these drugs, see Prescribing information.
Basis for recommendation
Basis for recommendation
Treatment recommendations are based on expert opinion from the British National Formulary (BNF), the Centers for Disease Control and Prevention, Principles and practice of infectious diseases, and the manufacturers' Summaries of Product Characteristics (SPCs) for metronidazole and tinidazole [Ravdin and Stauffer, 2005; ABPI Medicines Compendium, 2008b; ABPI Medicines Compendium, 2009a; BNF 57, 2009].
There is some debate in the literature over whether apparently non-invasive Entamoeba histolytica infection should be treated with antibiotics. However, in a low-endemic area such as the UK, treatment is generally recommended because of the potential for invasive disease to develop [Ravdin and Stauffer, 2005].
Metronidazole and tinidazole are licensed for the treatment of intestinal amoebiasis and extraintestinal disease [ABPI Medicines Compendium, 2008b; ABPI Medicines Compendium, 2009a].
Diloxanide is recommended after antibiotic treatment to destroy any amoebae cysts that may remain in the intestinal tract [Ravdin and Stauffer, 2005; World Gastroenterology Organisation, 2008].
Campylobacteriosis
How should I treat gastroenteritis caused by Campylobacter?
People with mild symptoms: antibiotic treatment is not usually necessary.
Consider antibiotic treatment for people:
With severe symptoms (high fever, bloody diarrhoea, or more than eight stools per day).
Who are immunocompromised.
Whose symptoms appear to be worsening.
Whose symptoms have lasted longer than 1 week.
If prescribing an antibiotic, a macrolide is preferred; ciprofloxacin is an alternative.
For more information on prescribing these drugs, see Prescribing information.
Basis for recommendation
Basis for recommendation
Treatment recommendations are based on expert opinion from the British National Formulary (BNF), the Centers for Disease Control and Prevention, the Health Protection Agency, and Principles and practice of infectious diseases [Blaser and Allos, 2005; BNF 57, 2009; HPA, 2009t].
Symptoms of campylobacteriosis are usually self-limiting and most people recover without treatment [BNF 57, 2009; HPA, 2009t].
Treatment with antibiotics should be considered for people with dysenteric symptoms, severe or persistent symptoms, or worsening infection, on the basis of anecdotal reports, clinical experience, and controlled trials [Blaser and Allos, 2005].
Treatment with antibiotics is recommended for people who are immunocompromised, because infection with Campylobacter can occasionally enter the bloodstream, and can be life-threatening in this population [CDC, 2008a].
Campylobacter jejuni is susceptible to a wide variety of antibiotics, including macrolides, tetracyclines, aminoglycosides, chloramphenicol, quinolones, nitrofurantoin, and clindamycin [Blaser and Allos, 2005].
Erythromycin is the drug of choice because it has good efficacy and is generally well tolerated. Alternative macrolides such as clarithromycin or azithromycin should be equally effective and may be considered if erythromycin is not tolerated.
Ciprofloxacin has activity against Campylobacter species; however, there is increasing resistance of Campylobacter to the quinolones in many parts of the world.
Cryptosporidiosis
How should I treat gastroenteritis caused by Cryptosporidium?
There are currently no effective antibiotics available to treat cryptosporidiosis.
Seek specialist advice regarding the management of people who are immunocompromised and those who are in poor health.
Basis for recommendation
Basis for recommendation
Treatment recommendations are based on expert opinion from the Centers for Disease Control and Prevention and the Principles and practice of infectious disease [Clinton White Jr., 2005; CDC, 2008g].
For most people, the symptoms of cryptosporidiosis usually settle within a few weeks with supportive treatment [CDC, 2008g].
People who are in poor health or who are immunocompromised are at higher risk for more severe and prolonged illness [CDC, 2008g].
For people with AIDS, effective anti-retroviral treatment can result in a reduction of the symptoms of cryptosporidiosis [Clinton White Jr., 2005; CDC, 2008g].
Escherichia coli 0157 (VTEC) infection
How should I treat gastroenteritis caused by Escherichia coli 0157 (VTEC)?
Management is entirely supportive; there is no specific treatment for gastroenteritis due to Vero cytotoxin-producing Escherichia coli 0157 (VTEC).
Discuss the individual's management, including the use and frequency of baseline blood tests (for example full blood count, blood film for fragmented blood cells, urea and electrolytes, lactate dehydrogenase, and C-reactive protein), with a specialist clinician.
Do not prescribe antibiotics for people with confirmed, probable, or suspected VTEC infection.
Avoid antimotility drugs, such as loperamide or diphenoxylate, and opioids in people with confirmed, probable, or suspected VTEC infection.
Advise people with confirmed, probable, or suspected VTEC infection not to use nonsteroidal anti-inflammatory drugs.
Urgently admit people with haemolytic uraemic syndrome for appropriate clinical management.
Most adults can go back to work 48 hours after the first normal stool. Consult public health authorities if the person handles food or works with vulnerable groups such as the elderly, the young, or people in poor health. Usually they should stay off work until two further stool tests, at least 48 hours apart, show that the bacteria have cleared.
Contacts of people with confirmed E. coli 0157 (VTEC) infection who work in any of the above groups may have to be excluded from work whilst a stool test is conducted to confirm they are not infected.
Basis for recommendation
Basis for recommendation
Treatment of E. coli
There is no evidence that antibiotics improve the course of disease. It is thought that treatment with some antibiotics may increase the risk of developing haemolytic uraemic syndrome (HUS), although a published meta-analysis showed no increase in the risk of HUS associated with antibiotic use [Safdar et al, 2002].
Treatments to avoid
There is no evidence to suggest that antibiotics improve the clinical course of Vero cytotoxin-producing E. coli (VTEC) infection, and they may increase the risk of HUS [Health Protection Network, 2008].
Antimotility drugs are not recommended, especially for people with bloody diarrhoea and possible VTEC infection, because retrospective analyses suggest these drugs are a risk factor for HUS or neurological complications [PHLS Advisory Committee on Gastrointestinal Infections, 2000; Health Protection Network, 2008].
Nonsteroidal anti-inflammatory drugs should be avoided because of their potential adverse effect on renal blood flow [Health Protection Network, 2008].
Return to work or school
The recommendations for returning to work follow advice from the Health Protection Agency [HPA, 2009u].
Giardiasis
How should I treat gastroenteritis caused by Giardia intestinalis?
Prescribe antibiotic treatment for all people with confirmed giardiasis.
Metronidazole is the drug of choice for treating giardiasis.
Tinidazole is an alternative to metronidazole.
For more information on prescribing these drugs, see Prescribing information.
Basis for recommendation
Basis for recommendation
Treatment recommendations are based on expert opinion from the British National Formulary, the Centers for Disease Control, and the manufacturer's Summary of Product Characteristics for metronidazole and tinidazole [ABPI Medicines Compendium, 2008b; CDC, 2008d; ABPI Medicines Compendium, 2009a; BNF 57, 2009].
Salmonellosis (non-typhoidal)
How should I treat gastroenteritis caused by Salmonella?
Antibiotic treatment is not recommended for healthy individuals with gastroenteritis due to Salmonella infection.
Consider antibiotic treatment for people who:
Are older than 50 years of age.
Are immunocompromised.
Have cardiac valve disease or endovascular abnormalities, including prosthetic vascular grafts.
The antibiotic of choice is ciprofloxacin (check with the microbiology laboratory that the isolate is sensitive).
For more information on prescribing ciprofloxacin, see Prescribing information.
Basis for recommendation
Basis for recommendation
A Cochrane systematic review showed no evidence of benefit of antibiotic treatment in healthy individuals with Salmonella gastroenteritis; however, there was an increased risk of adverse effects, and carriage of Salmonella was prolonged [Sirinavin and Garner, 1999].
Older people, those who are immunocompromised, and people with cardiac valvular or endovascular abnormalities (including prosthetic vascular grafts), have an increased risk of invasive infection and may benefit from early antimicrobial treatment [Hsu and Lin, 2005; Pegues et al, 2005].
The choice of antibiotics is based on expert opinion in the British National Formulary [BNF 57, 2009].
Shigellosis
How should I treat gastroenteritis caused by Shigella?
Seek advice from the local microbiologist regarding antibiotic management.
Antibiotic treatment is usually recommended for all people with shigellosis.
The antibiotics of choice are ciprofloxacin or azithromycin (off-label).
Amoxicillin or trimethoprim can also be used if the organism is sensitive.
Antimotility drugs such as loperamide or diphenoxylate should be avoided.
For more information on prescribing these drugs, see Prescribing information.
Basis for recommendation
Basis for recommendation
Treatment recommendations are based on expert opinion from the British National Formulary, and the Centers for Disease Control and Prevention [CDC, 2008f; BNF 57, 2009].
There is some debate in the literature over whether people with mild disease should receive antibiotics. Appropriate antibiotic treatment prevents transmission from person to person, and may shorten the duration of gastroenteritis by several days; it is therefore recommended by several sources [DuPont, 2005; CDC, 2008f].
Antimotility drugs can make shigella gastroenteritis worse and are therefore not recommended [CDC, 2008f].
Follow-up advice
What advice should I give about follow up?
Advise the person to seek medical advice if:
Their condition does not improve within 48 hours.
Symptoms exacerbate or their condition worsens.
Warning signs or symptoms develop (such as severe vomiting or dehydration, persistent fever, abdominal distension, or frank blood in stools).
Basis for recommendation
Basis for recommendation
This recommendation is based on expert opinion in a guideline on self-medication for the treatment of acute diarrhoea [Wingate et al, 2001].
Notifying public health authorities
When should I notify public health authorities?
Notify the Local Authority Proper Officer (in England and Wales, the local Consultant in Communicable Disease Control) if a case of any of the following is suspected:
Cholera.
Bloody diarrhoea presumed to be due to gastroenteritis.
Food poisoning (organisms that can be implicated in food poisoning include Campylobacter, Escherichia coli O157:H7, Salmonella, Shigella, Giardia, Yersinia enterolytica, Entamoeba histolytica, and norovirus).
Haemolytic uraemic syndrome (HUS).
Complete an official Formal Notification Certificate (from a pad supplied locally) immediately on diagnosis of a suspected notifiable disease and return it to where the pad was obtained within 3 days (this could be the Local Authority, Primary Care Trust, or Health Protection Unit).
If urgent notification is needed (such as for suspected cholera, infectious bloody diarrhoea, haemolytic uraemic syndrome, clusters or outbreaks of food poisoning) telephone the local Health Protection Unit with the details. A Formal Notification Certificate must still be sent within 3 days.
Notify and act on the advice of the public health authorities if an outbreak of gastroenteritis is suspected.
Contact details for Health Protection Units in England can be found through the Local and Regional Services page on the Health Protection Agency website www.hpa.org.uk and for health protection teams for Wales on the National Public Health Service for Wales website www.wales.nhs.uk.
Basis for recommendation
Basis for recommendation
Which diseases to notify
This recommendation is based on the 1988 Public Health (Infectious Diseases) Regulations [DH, 2010].
How to notify
The recommendation on what action to take in the event of a suspected diagnosis of a notifiable disease is based on expert advice from the Health Protection Agency and the Department of Health [HPA, 2010; HPA, 2009a; DH, 2010].
The recommendation on what action to take if an outbreak is suspected is based on the National Institute for Health and Clinical Excellence (NICE) guideline Diarrhoea and vomiting caused by gastroenteritis: diagnosis, assessment, and management in children younger than 5 years [NICE, 2009].
The definition of who fulfils the role of the Proper Officer is based on guidelines from the British Society for the Study of Infection [Farthing et al, 1996].
Important aspects of prescribing information relevant to primary healthcare are covered in this section specifically for the drugs recommended in this CKS topic. For further information on contraindications, cautions, drug interactions, and adverse effects, see the electronic Medicines Compendium (eMC) (http://medicines.org.uk/emc), or the British National Formulary (BNF) (www.bnf.org).
Metronidazole
Metronidazole
Information for prescribers
What issues should I consider when prescribing metronidazole?
The dose and duration of metronidazole depends on the indication [ABPI Medicines Compendium, 2008b; BNF 57, 2009]. The recommended doses for adults are:
Mild-to-moderate intestinal amoebiasis: metronidazole 400 mg three times a day for 5–10 days (followed by diloxanide for 10 days).
Amoebic dysentery: metronidazole 800 mg three times a day for 5 days (followed by diloxanide for 10 days).
Giardiasis: metronidazole 2 g once a day for 3 days, or metronidazole 400 mg three times a day for 5 days.
Common adverse effects include a metallic taste and gastrointestinal irritation (in particular nausea and vomiting). These are more common at higher doses.
Interaction with warfarin: metronidazole can enhance the anticoagulant effect of warfarin. Monitor the international normalized ratio (INR) when both drugs are used and adjust the warfarin dose accordingly [Baxter, 2008].
Interaction with alcohol: some people taking oral metronidazole experience a disulfiram-like reaction to alcohol (flushing, increased respiratory rate, increased pulse rate) [Baxter, 2008].
This interaction is controversial because the incidence has been reported to be between 0% and 100%.
Although there is no conclusive evidence to support an interaction between metronidazole and alcohol, people taking metronidazole should be advised of the possible consequences of drinking alcohol.
Advice for patients
What advice should I give the person about taking metronidazole?
Warn the person that they might experience a disulfiram-like reaction (such as flushing, nausea, headache, dizziness) if they also drink alcohol [Baxter, 2008].
Oral hormonal contraception — additional contraceptive precautions are not required during or after courses of metronidazole [FSRH, 2011].
However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on Antibiotics in the CKS topic on Contraception - assessment.
Pregnancy and breastfeeding
Can metronidazole be used during pregnancy or breastfeeding?
Pregnancy: metronidazole can be used during pregnancy, but the manufacturer advises that high-dose regimens are best avoided [ABPI Medicines Compendium, 2008b]. Metronidazole has been in clinical use for a long time, and experience suggests that it is not teratogenic in humans [Schaefer et al, 2007]. A recent prospective controlled study in 228 women exposed to metronidazole in pregnancy, 86% of whom had first-trimester exposure, confirm these findings [Schaefer et al, 2007].
Breastfeeding: metronidazole is passed into breast milk in significant amounts, and its half-life is prolonged in the newborn period [Schaefer et al, 2007]. The manufacturer advises avoidance of high-dose regimens [ABPI Medicines Compendium, 2008b], whilst others suggest that, if a single dose regimen is being used, the dose could be given after the last breastfeed at night to minimize exposure of the infant [Schaefer et al, 2007].
Ciprofloxacin
Ciprofloxacin
Information for prescribers
What issues should I consider when prescribing ciprofloxacin?
The dose and duration of ciprofloxacin depends on the indication [ABPI Medicines Compendium, 2008c]:
Campylobacter infection (if indicated): ciprofloxacin 500 mg twice a day for 5–7 days.
Non-typhoidal salmonellosis (if indicated): ciprofloxacin 500 mg twice a day for 1 day only.
Shigellosis: ciprofloxacin 500 mg twice a day for 1 day only; continue for 5 days if the organism is Shigella dysenteriae.
In moderate or severe renal impairment, use half the normal ciprofloxacin dose [BNF 57, 2009].
Avoid ciprofloxacin in people with epilepsy or conditions that predispose to seizures, and in people taking other medication that may predispose to seizures, as quinolones can lower seizure threshold. Seizures have rarely occurred in people without a previous history of seizures; concurrent use of nonsteroidal anti-inflammatory drugs or theophylline may increase the risk [CSM, 1991].
Quinolones can very rarely cause tendon damage; the risk of tendon rupture is increased by co-administration of corticosteroids. If tendinitis is suspected (if pain or inflammation of a tendon occurs), treatment should be stopped [CSM, 2002].
Advice for patients
Advise the person that ciprofloxacin can occasionally cause drowsiness and may impair the performance of skilled tasks (such as driving).
Advise the person that if they experience pain or inflammation of a tendon they should urgently consult a healthcare professional.
Oral hormonal contraception — additional contraceptive precautions are not required during or after courses of ciprofloxacin [FSRH, 2011].
However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on Antibiotics in the CKS topic on Contraception - assessment.
Pregnancy and breastfeeding
Pregnancy: ciprofloxacin should not be used during pregnancy. Although the use of quinolones has not been associated with an increased risk of major malformations or other adverse outcomes in pregnancy, they have been shown to cause damage to immature cartilage in animal studies [Schaefer et al, 2007; ABPI Medicines Compendium, 2008c].
Breastfeeding: avoid ciprofloxacin in breastfeeding women. Quinolones are excreted into breast milk, and in animal studies they have been shown to irreversibly damage growing cartilage [Schaefer et al, 2007; ABPI Medicines Compendium, 2008c].
Macrolides
Macrolides
Information for prescribers
What issues should I consider when prescribing a macrolide?
The dose and duration depends on the indication [Blaser and Allos, 2005]:
Campylobacter infection (if indicated): erythromycin 250 mg to 500 mg four times a day for 5–7 days.
Shigellosis: azithromycin 500 mg once a day for 3 days (off-label).
Adverse effects
Gastrointestinal adverse effects are common in people taking erythromycin. Consider using clarithromycin in people who have had problems with gastrointestinal effects in the past when taking erythromycin. Clarithromycin usually has milder gastrointestinal adverse effects [BNF 57, 2009].
Drug interactions
Possible increased levels of aminophylline or theophylline (and increased risk of theophylline toxicity) [Baxter, 2008]:
Consider using clarithromycin (or azithromycin) in preference to erythromycin as they normally cause only modest (clinically unimportant) increases in theophylline levels.
Check theophylline levels if toxicity is suspected (for example palpitations, nausea, headache).
Possible increased levels of carbamazepine (and increased risk of carbamazepine toxicity) with erythromycin and clarithromycin [Baxter, 2008]:
Consider using azithromycin instead (interaction reported not to occur), or
Consider reducing the dose of carbamazepine by 30–50% during treatment with erythromycin or clarithromycin, and advise the person to report symptoms of toxicity (such as dizziness, diplopia, ataxia, confusion).
Possible enhanced effect of warfarin. This is an established but unpredictable interaction.
Monitor the international normalized ratio (INR) when a macrolide is added to warfarin, and adjust the warfarin dose accordingly [Baxter, 2008].
Possible QT interval prolongation.
If possible, avoid erythromycin or clarithromycin in people taking a drug that can potentially prolong the QT interval (for example antiarrhythmics, antipsychotics, tricyclic antidepressants) or if the person has hypokalaemia, which also increases the risk of QT interval prolongation [Baxter, 2008].
Possible increased levels of some statins (increased risk of myopathy in people taking atorvastatin or simvastatin) [CSM, 2004]:
Stop atorvastatin or simvastatin for the duration of erythromycin or clarithromycin treatment [MHRA, 2008; ABPI Medicines Compendium, 2009b].
Consider using azithromycin instead, but advise the person to report any muscle symptoms [Sweetman, 2005].
Advice for patients
What advice should I give the person about taking a macrolide?
Oral hormonal contraception — additional contraceptive precautions are not required during or after courses of erythromycin or clarithromycin [FSRH, 2011].
However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on Antibiotics in the CKS topic on Contraception - assessment.
Advise people taking concomitant warfarin, statins, carbamazepine, theophylline, or aminophylline to seek advice if symptoms of toxicity to these drugs occur during treatment with a macrolide.
Pregnancy and breastfeeding
Can macrolides be used during pregnancy or breastfeeding?
Pregnancy: if a macrolide is required during pregnancy, erythromycin is the drug of choice.
Data from more than 7000 pregnancies does not indicate that erythromycin is associated with an increased risk of congenital malformations or any other adverse fetal effects. A recent study has suggested a possible increased risk of cardiovascular malformations and pyloric stenoses; however, causality has not been established and the individual risk, if any, is thought to be low [NTIS, 2008c].
There are fewer published data on the use of azithromycin during pregnancy and breastfeeding. The limited published data and follow-up data collected by the UK Teratology Information Service (UKTIS), (formerly the National Teratology Information Service [NTIS]), do not demonstrate an increased risk of congenital malformations following exposure to azithromycin in human pregnancy [NTIS, 2008b].
Breastfeeding: if a macrolide is required during breastfeeding, erythromycin is the drug of choice.
Low levels of erythromycin are excreted in breast milk, and are considered to be unlikely to cause adverse effects in the infant [BNF 57, 2009].
Diloxanide
Diloxanide
Information for prescribers
The dose of diloxanide for amoebiasis is 500 mg three times a day for 10 days. This should be started on completion of metronidazole or tinidazole treatment [BNF 57, 2009].
No serious adverse effects have been reported. The most common adverse effects include flatulence, vomiting, pruritus, and urticaria.
Pregnancy and breastfeeding
Diloxanide is not suitable for use during pregnancy and breastfeeding as there are no safety data to support its use [BNF 57, 2009].
Antimotility drugs (loperamide)
Antimotility drugs (loperamide)
Information for prescribers
Cautions and contraindications
Children younger than 12 years of age: loperamide is licensed for use in children 4 years of age and older, but antimotility drugs are not recommended for children less than 12 years of age [BNF for Children, 2008].
Do not use loperamide in people with conditions where inhibition of peristalsis should be avoided (for example abdominal distension), acute diarrhoeal conditions (for example active ulcerative colitis or antibiotic-associated colitis). Do not use loperamide alone in people with dysentery (blood or mucus in the stools and fever) [ABPI Medicines Compendium, 2008a].
Adverse effects
The most commonly reported adverse effects are constipation and dizziness.
Rarely reported adverse effects include abdominal cramps, drowsiness, skin reactions (including urticaria), paralytic ileus, and abdominal bloating.
Serious adverse effects have been reported with loperamide in children, such as necrotizing enterocolitis, neurological symptoms, delirium, respiratory depression, coma, and death [American Academy of Pediatrics, 1996; National Collaborating Centre for Women's and Children's Health, 2009].
Pregnancy and breastfeeding
Pregnancy: loperamide is not recommended during pregnancy because there is no evidence for its safety. However, there are no data to suggest an increased risk of fetal malformations following the use of loperamide in pregnancy [NTIS, 2008a].
Breastfeeding: loperamide has a good safety profile for short-term use in women who are breastfeeding [UKMiCentral, 2004].
Evidence
Evidence
Supporting evidence
Children
Antibiotic treatment
Evidence on antibiotic treatment
A review of the literature was undertaken by the Guideline Development Group (GDG) of the National Institute for Health and Clinical Excellence (NICE). The review included 14 randomized controlled trials (RCTs) and one Cochrane systematic review comparing antibiotic treatment with placebo or no treatment [National Collaborating Centre for Women's and Children's Health, 2009].
Salmonella
The NICE review included four RCTs of antibiotic treatment (amoxicillin, ampicillin, azithromycin, cefixime, or co-trimoxazole) in children with salmonella. These were generally of poor quality.
The trials consistently showed that antibiotic treatment did not significantly reduce the duration of diarrhoea.
One further retrospective review identified the following as risk factors for the development of invasive salmonellosis (bacteraemia or meningitis):
Age less than 6 months.
Temperature greater than 38°C.
Dehydration.
Campylobacter
The NICE review included three RCTs comparing antibiotic treatment (erythromycin) with placebo or no treatment in children with Campylobacter-associated gastroenteritis. One of these studies was not sufficiently powered to detect any significant differences between the treatment groups. Results from the other two trials were conflicting.
One trial found no significant difference between the two groups in the duration of diarrhoea. In the other trial the duration of diarrhoea was significantly reduced in the erythromycin group, although the cure rate at day 5 was similar in both groups.
Yersinia
The NICE review included one RCT comparing antibiotic treatment (co-trimoxazole) with placebo or no treatment in children with Yersinia-associated enteritis. The study was small (45 participants) and there was about 25% loss to follow up.
There was no significant difference between antibiotic treatment and placebo for the duration of diarrhoea, the number of people with diarrhoea for less than 7 days, and recurrence of diarrhoea.
Shigella
The NICE review included one RCT comparing antibiotic treatment (ampicillin) with placebo or no treatment in children with confirmed Shigella, Salmonella, or Escherichia coli infection. Only 37 children in this study had Shigella infection.
There was no significant difference between the treatment and placebo groups for the mean number of days until diarrhoea improved, and mean number of days until diarrhoea stopped. Treatment with ampicillin significantly reduced the mean number of days until the child became afebrile compared with placebo, and the mean number of days until the child's stool culture became negative.
E. coli
The NICE review included one RCT comparing antibiotic treatment (ampicillin) with placebo or no treatment in children with confirmed Shigella, Salmonella, or E. coli. Only 35 children in this study had E. coli infection.
There were no significant differences between the treatment and placebo groups in the mean number of days until diarrhoea improved or ceased or in the mean number of days until the child became afebrile or stool culture negative.
E. coli O157:H7 and haemolytic uraemic syndrome (HUS)
The NICE review included two cohort studies of children with diarrhoea caused by E. coli O157:H7, the main cause of HUS.
In the first study (a prospective cohort) significantly more children who were given antibiotics developed HUS, although the confidence interval was wide and the precision of this finding is low. A significant linear trend was seen for initial white blood cell count and the development of HUS.
In the second study (a retrospective cohort), the development of HUS was associated with increased white blood cell count and with vomiting in children younger than 5.5 years of age. There was no significant difference in the development of HUS between children who received an antibiotic and those who did not, or between children who received an antimotility drug and those who did not.
Cryptosporidium
The NICE review included two studies comparing antibiotic treatment (nitazoxanide [an antiparasitic drug] or co-trimoxazole) with placebo or no treatment in children with confirmed cryptosporidiosis. One study was undertaken in Zambia, and there is some doubt about the generalizability of the results; the other study was methodologically poor.
In the first study from Zambia, significantly more children in the nitazoxanide group were reported as being well (symptom-free) at day 7 compared with the placebo group. Significantly more children in the nitazoxanide group also had a microbiological response (two negative stool examinations) at day 7.
Results from the second (potentially biased) study suggest that nitazoxanide, but not co-trimoxazole, was effective in achieving a microbiological cure.
Empirical treatment
The NICE review included four studies comparing antibiotic treatment (co-trimoxazole or erythromycin) with placebo or no treatment in children without confirmation of a specific pathogen.
These studies were undertaken in South Africa and Mexico over 20 years ago and, although there was some evidence that empirical antibiotics had some benefit in reducing the duration of symptoms, the GDG did not consider that these studies were relevant to the current UK setting.
Traveller's diarrhoea
The NICE review identified no trials of antibiotic treatment for traveller's diarrhoea in children. However, results from a Cochrane systematic review in adults with traveller's diarrhoea found that antibiotic treatment was effective in reducing the duration and severity of diarrhoea, although there was an increase in the incidence of adverse effects. See the CKS topic on Diarrhoea - prevention and advice for travellers for details.
Antimotility drugs
Evidence on antimotility drugs
The Guideline Development Group (GDG) of the National Institute for Health and Clinical Excellence (NICE) considered evidence from one well-conducted systematic review and meta-analysis (search date: to 2006), which included 13 randomized controlled trials comparing loperamide with placebo for the treatment of diarrhoea in children younger than 12 years of age [Li et al, 2007]. Compared with children in the placebo group:
Significantly fewer children in the loperamide group continued to have diarrhoea at 24 hours (relative risk [RR] 0.66, 95% CI 0.57 to 0.78).
Children in the loperamide group had a significantly shorter duration of diarrhoea (weighted mean difference 0.80 days, 95% CI 0.87 to 0.74).
Children in the loperamide group had a significantly lower stool count at 24 hours (count ratio 0.84, 95% CI 0.77 to 0.92).
Serious adverse events (defined as ileus, lethargy, or death) were reported in eight of the 927 children allocated to loperamide (0.9%, 95% CI 0.4% to 1.7%). No serious adverse events were reported in any of the 764 children allocated to placebo. Among the children allocated to loperamide, serious adverse events were reported only among children younger than 3 years of age.
Anti-emetics
Evidence on anti-emetics
A review of the literature was undertaken by the Guideline Development Group (GDG) of the National Institute for Health and Clinical Excellence (NICE). The review included five randomized controlled trials (RCTs) comparing anti-emetic treatment with placebo or another anti-emetic [National Collaborating Centre for Women's and Children's Health, 2009]. A Cochrane systematic review (search date: June 2008) included four of these studies, which compared an anti-emetic with placebo [Alhashimi et al, 2009].
Three of the studies compared oral ondansetron with placebo, one study compared intravenous (IV) ondansetron or IV dexamethasone with placebo, and one study compared IV ondansetron or IV metoclopramide with placebo. All five studies took place in an emergency department or hospital setting.
Oral ondansetron versus placebo
After pooling data from two studies, oral ondansetron was significantly more effective than placebo at stopping vomiting in the first few hours after treatment (RR 1.32, 95% CI 1.17 to 1.49).
After pooling data from all three studies, significantly fewer children in the ondansetron group required IV rehydration therapy (RR 0.37, 95% CI 0.17 to 0.82).
Two of the three trials reported that children receiving ondansetron experienced significantly more episodes of diarrhoea.
Other anti-emetics
In one small RCT there was no evidence of a difference in cessation of vomiting in children receiving IV ondansetron, IV metoclopramide, or placebo.
In a second RCT, fewer children in the ondansetron group required admission to hospital, and more tolerated oral rehydration therapy more quickly than those in the placebo group. There was no evidence of a significant difference between the IV dexamethasone and placebo groups.
Probiotics
Evidence on probiotics
A review of the literature was undertaken by the Guideline Development Group (GDG) of the National Institute for Health and Clinical Excellence (NICE). The review included three systematic reviews and four randomized controlled trials comparing probiotic treatment with placebo or no treatment [National Collaborating Centre for Women's and Children's Health, 2009].
The review identified evidence from high quality systematic reviews suggesting that treatment with probiotics has a beneficial effect in children with gastroenteritis. However, the studies included in the review varied in quality, the specific probiotics studied, and the outcomes examined. The GDG did not therefore consider it appropriate to recommend the use of a probiotic.
Adults
Antibiotic treatment
Evidence on antibiotic treatment
Empirical antibiotic treatment
Evidence on empirical antibiotic treatment
Evidence from three small randomized controlled trials (RCTs) suggests that empirical ciprofloxacin or ofloxacin reduces the duration of diarrhoea by about 1 day. There is conflicting evidence regarding the number of people cured or improved.
Three RCTs have investigated the use of empirical ciprofloxacin, ofloxacin, and co-trimoxazole for the management of acute diarrhoea. One RCT in 202 participants compared three interventions: ciprofloxacin 500 mg, co-trimoxazole 160/800 mg, and placebo, given twice a day for 5 days [Goodman et al, 1990]. A second RCT in 117 participants compared single-dose ofloxacin 400 mg with placebo [Noguerado et al, 1995]. The third RCT in 173 participants compared ciprofloxacin 500 mg twice a day with placebo [Dryden et al, 1996].
Duration of diarrhoea
In the first RCT, the duration of the diarrhoea was significantly shorter with ciprofloxacin (2.4 days) than with placebo (3.4 days). Co-trimoxazole did not reduce the duration of diarrhoea compared with placebo.
In the second RCT, there was no significant difference between ofloxacin and placebo in the average duration of diarrhoea (2.56 +/– 2.21 days in the ofloxacin group versus 3.41 +/– 2.5 days in the placebo group; p = 0.117).
In the third RCT, ciprofloxacin significantly reduced the average duration of diarrhoea, which was 2.2 days for people in the ciprofloxacin group and 4.6 days in the placebo group (p = 0.0001).
Proportion of people cured or improved
In the first RCT, ciprofloxacin significantly increased the proportion of people cured or improved by days 1, 3, 4, and 5 compared with placebo. Co-trimoxazole significantly increased the proportion of people cured or improved compared with placebo on day 3, but not on days 1, 4, or 5.
In the second RCT, there was no significant difference between the ofloxacin and placebo groups in the proportion of people whose symptoms were unchanged for more than 48 hours.
Antibiotic treatment for travellers diarrhoea
Evidence on antibiotic treatment for travellers diarrhoea
Empirical antibiotic treatment in people with travellers' diarrhoea is associated with a reduction in the duration and severity of diarrhoea, but a higher incidence of adverse effects.
A Cochrane systematic review has assessed the efficacy of empirical antibiotics in adults and children (5 years of age or older) with travellers' diarrhoea (acute non-bloody diarrhoea in people travelling outside their usual country of residence, and resident in the country of study for less than 6 months) [de Bruyn et al, 2000]. A further literature search for this Cochrane systematic review in 2003 did not find any new evidence to necessitate an update to the text. The review included 20 randomized controlled trials (RCTs), 12 of which were placebo-controlled.
Antibiotic compared with placebo
Duration of diarrhoea: meta-analysis for the primary outcome (duration of diarrhoea in placebo-controlled trials) was not considered feasible.
All of the 10 trials reported a significant reduction in duration of diarrhoea in people treated with antibiotics.
Cure at 72 hours: data were pooled from six studies reporting cure at 72 hours.
Significantly more people in the antibiotic group were cured of diarrhoea at 72 hours (odds ratio [OR] 5.90, 95% CI 4.06 to 8.57, 697 people).
Severity of symptoms: data from two trials reported severity of symptoms (the number of unformed stools in a 24-hour period) at 24, 48, and 72 hours.
During each 24-hour period there was a small reduction in severity of symptoms with antibiotic.
Adverse effects: five studies reported adverse effects.
People in the antibiotic group reported significantly more adverse effects (OR 2.37, 95% CI 1.50 to 3.75). Details of the adverse effects were not reported, but most were minor or resolved on stopping the antibiotic.
One RCT published subsequent to the Cochrane systematic review also favoured antibiotic treatment over placebo.
One RCT compared rifaximin with placebo and ciprofloxacin in 399 adult travellers [Taylor et al, 2006].
The median time to the last unformed stool was significantly less in the rifaximin and ciprofloxacin groups compared with placebo; the difference between the two antibiotic groups was not significant (median time 32.0 hours with rifaximin, 65.5 hours with placebo, 28.8 hours with ciprofloxacin).
Loperamide
Evidence on loperamide
There is limited evidence that loperamide reduces the frequency and duration of diarrhoea in adults with traveller's diarrhoea or non-specific diarrhoea. The magnitude of improvement varies considerably between studies.
CKS identified a guideline for adults on self-medication for the treatment of acute diarrhoea [Wingate et al, 2001]. A systematic search does not appear to have been done. The guideline developers identified six studies of loperamide; all were in travellers' diarrhoea, and in most loperamide was given in addition to antibiotics.
The guideline group concluded that the balance of evidence suggests that anti-diarrhoeal medication reduces the frequency and duration of diarrhoea.
The guideline group found no evidence that loperamide has adverse effects in people with infectious non-dysenteric traveller's diarrhoea, even if caused by Escherichia coli, Shigella, Campylobacter, or Salmonella.
CKS identified several additional randomized controlled trials (RCTs) of antimotility drugs (diphenoxylate or loperamide) in the management of acute, non-specific diarrhoea in adults in developed countries.
Diphenoxylate compared with placebo
In one RCT in 152 people with acute diarrhoea, diphenoxylate significantly reduced the frequency (p = 0.046) and duration (p = 0.025) of diarrhoea compared with placebo [Lustman et al, 1987].
Loperamide hydrochloride compared with placebo
Two RCTs have compared loperamide hydrochloride with either placebo or with loperamide oxide in adults with acute, non-specific diarrhoea [Hughes, 1995; Van Den Eynden and Spaepen, 1995]. In both studies, the time to complete relief of diarrhoea was significantly reduced for the group treated with loperamide hydrochloride compared with placebo:
First study (409 participants): 27 hours versus 45.25 hours (p = 0.006).
Second study (261 participants): 17.5 hours versus 37 hours (p = 0.007).
There was no evidence of a significant difference between loperamide hydrochloride and loperamide oxide in either of the studies.
Loperamide oxide compared with placebo
Four RCTs have compared loperamide oxide with placebo in adults with acute non-specific diarrhoea [Dettmer, 1994; Dreverman and Van der Poel, 1995; Hughes, 1995; Van Den Eynden and Spaepen, 1995].
In all studies the time to complete relief of diarrhoea was significantly reduced for the group treated with loperamide oxide.
The difference ranged from 7.75 hours to 21.75 hours with loperamide oxide 1 mg, and from 15.60 hours to 19.75 hours with loperamide oxide 2 mg.
Loperamide hydrochloride compared with bismuth subsalicylate
Two RCTs have compared loperamide with bismuth subsalicylate, one in the management of acute diarrhoea [DuPont et al, 1990], and one in the management of non-dysenteric traveller's diarrhoea [Johnson et al, 1986].
The first open-label study compared loperamide hydrochloride with bismuth subsalicylate in 203 adults with non-specific gastroenteritis.
Treatment with loperamide significantly reduced the average number of unformed stools compared with bismuth subsalicylate in the first 12 hours after treatment (0.9 versus 2.3; p = 0.0001).
Treatment with loperamide significantly reduced the time to the last unformed stool compared with bismuth subsalicylate (9.9 hours versus 17.3 hours; p < 0.0004).
Both treatments were well tolerated with only minor adverse effects reported, none of which led to withdrawal from the study.
The second study compared loperamide hydrochloride with bismuth subsalicylate in 219 adults with acute traveller's diarrhoea without dysenteric symptoms.
Treatment with loperamide significantly reduced the average number of unformed stools compared with bismuth subsalicylate in the first 4 hours after treatment (0.9 versus 1.3; p < 0.004); this difference continued up to 48 hours after treatment.
Constipation was experienced more frequently in people in the loperamide group compared with bismuth subsalicylate (eight people versus one person; p < 0.025).
Probiotics
Evidence on probiotics
Probiotics appear to be effective at reducing the duration of diarrhoea. However, there is insufficient information regarding specific regimens of probiotics to make recommendations regarding their use.
A Cochrane systematic review (search date: to December 2002) has assessed the efficacy of probiotics in diarrhoea that was proven or presumed to be infectious [Allen et al, 2003]. The review included randomized controlled trials (RCTs) of a specific, identified probiotic compared with placebo or no probiotic in adults and children with acute diarrhoea (duration less than 14 days). The review included 23 RCTs in 1917 people; there was significant variation in the probiotic used, the methodological quality of the studies, and the outcomes assessed.
Cure at 72 hours (15 RCTs, 1341 participants)
The proportion of people with diarrhoea lasting for 3 days or longer was significantly less in the probiotic group than the control group (41% versus 62%; risk ratio [RR] 0.66, 95% CI 0.55 to 0.77).
Mean duration of diarrhoea (12 RCTs, 970 participants)
Probiotics significantly reduced the mean duration of diarrhoea compared with control (mean difference 30.5 hours, 95% CI 18.5 to 42.5).
Adults compared with children
Probiotics appeared to reduce diarrhoea more in adults than in children; however, there was significant heterogeneity in the sub-group analyses.
Adverse effects
Twelve of the studies reported that no adverse events occurred, eight studies did not report information on adverse events, and three studies reported the occurrence of an adverse event (vomiting).
Anti-emetics
Evidence on anti-emetics
CKS found no published randomized controlled trials (RCTs) in adults that compared the effectiveness of anti-emetics with placebo. One small RCT found that intravenous prochlorperazine was more effective than intravenous promethazine for adults with nausea and vomiting associated with gastroenteritis.
One small RCT randomized adults with gastroenteritis to receive prochlorperazine 10 mg intravenously or promethazine 25 mg intravenously [Ernst et al, 2000]. The primary endpoints were the degrees of relief at 30 minutes and at 60 minutes.
At 30 minutes and at 60 minutes after receiving medication, prochlorperazine worked significantly better than promethazine (p = 0.004 at 30 minutes and p < 0.001 at 60 minutes).
The time to complete relief was significantly shorter with prochlorperazine (p = 0.021).
Search strategy
Scope of search
A literature search was conducted for guidelines, systematic reviews and randomized controlled trials on the primary care management of Gastroenteritis with additional searches in the following areas:
Procedures for stool sampling and laboratory investigations
Microbiological causes
Notifiable disease recommendations
Referral criteria
The search excluded Clostridium difficile and antibiotic associated diarrhoea.
Search dates
Medline and Embase
January 2006 – July 2009
Key search terms
Various combinations of searches were carried out. The terms listed below are the core search terms that were used for Medline and these were adapted for other databases. Further details are available on request.
exp Gastroenteritis/, exp Diarrhea/, exp Vomiting/, diarrhoea.tw, diarrhea.tw, vomiting.tw, gastroenteritis.tw
exp "Laboratory Techniques and Procedures"/
exp Food Poisoning/, Food Poisoning.tw, exp Food Handling/, exp Food Contamination/
exp Giardiasis/, exp Giardia/, exp Norovirus/, exp Rotavirus/, exp Listeria Infections/, exp Listeria/, exp Amebiasis/, exp Campylobacter Infections/, exp Campylobacter/, exp Shigella/
exp Specimen Handling/, exp Feces/
exp Anti-Bacterial Agents/, exp Ciprofloxacin/
exp Antiemetics/, exp Ondansetron/
exp Parasympatholytics/
exp Antidiarrheals/
exp Aluminum Hydroxide/, aluminium hydroxide.tw
exp Fluid Therapy/, rehydration.tw, exp Rehydration Solutions/
exp Bismuth/, bismuth.tw, bismuth subsalicylate.tw
exp Probiotics/
exp Hygiene/
exp "Referral and Consultation"/
exp Disease Notification/
Table 1. Key to search terms.| Search commands | Explanation |
|---|---|
| / | indicates a MeSH subject heading with all subheadings selected |
| .tw | indicates a search for a term in the title or abstract |
| exp | indicates that the MeSH subject heading was exploded to include the narrower, more specific terms beneath it in the MeSH tree |
| $ | indicates that the search term was truncated (e.g. wart$ searches for wart and warts) |
Topic specific literature search sources
Centers for Disease Control and Prevention
National Institute for Health and Clinical Excellence
World Gastroenterology Organisation
Sources of guidelines
Scottish Intercollegiate Guidelines Network (SIGN)
National Guidelines Clearinghouse
British Columbia Medical Association
Dutch College of General Practitioners
Institute for Clinical Systems Improvement
Guidelines International Network
National Library of Guidelines
National Health and Medical Research Council (Australia)
University of Michigan Medical School
Michigan Quality Improvement Consortium
National Resource for Infection Control
NHS Scotland National Patient Pathways
Agency for Healthcare Research and Quality
UK Ambulance Service Clinical Practice Guidelines
RefHELP NHS Lothian Referral Guidelines
Medline (with guideline filter)
Sources of systematic reviews and meta-analyses
Systematic reviews
Protocols
Database of Abstracts of Reviews of Effects
Medline (with systematic review filter)
EMBASE (with systematic review filter)
Sources of health technology assessments and economic appraisals
NIHR Health Technology Assessment programme
NHS Economic Evaluations
Health Technology Assessments
Canadian Agency for Drugs and Technologies in Health
International Network of Agencies for Health Technology Assessment
Sources of randomized controlled trials
Central Register of Controlled Trials
Medline (with randomized controlled trial filter)
EMBASE (with randomized controlled trial filter)
Sources of evidence based reviews and evidence summaries
DynaMed
Central Services Agency COMPASS Therapeutic Notes
Sources of national policy
Health Management Information Consortium (HMIC)
References
ABPI Medicines Compendium (2008a) Summary of product characteristics for Imodium capsules. Electronic Medicines Compendium..Datapharm Communications Ltd.www.medicines.org.uk
ABPI Medicines Compendium (2008b) Summary of product characteristics for Flagyl tablets 200mg and 400mg. Electronic Medicines Compendium..Datapharm Communications Ltd.www.medicines.org.uk
ABPI Medicines Compendium (2008c) Summary of product characteristics for Ciproxin tablets 500mg. Electronic Medicines Compendium..Datapharm Communications Ltd.www.medicines.org.uk [Free Full-text]
ABPI Medicines Compendium (2009a) Summary of product characteristics for Fasigyn. Electronic Medicines Compendium..Datapharm Communications Ltd.www.medicines.org.uk [Free Full-text]
ABPI Medicines Compendium (2009b) Summary of product characteristics for Zocor 10mg, 20mg, 40mg and 80mg film-coated tablets. Electronic Medicines Compendium..Datapharm Communications Ltd.www.medicines.org.uk [Free Full-text]
Alhashimi, D., Al-Hashimi, H. and Fedorowicz, Z. (2009) Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents (Cochrane Review). The Cochrane Library.Issue 2.John Wiley & Sons, Ltd.www.thecochranelibrary.com [Free Full-text]
Allen, S., Okoko, B., Martinez, E. et al. (2003) Probiotics for treating infectious diarrhoea (Cochrane Review). The Cochrane Library.Issue 4.John Wiley & Sons, Ltd.www.thecochranelibrary.com [Free Full-text]
American Academy of Pediatrics (1996) Practice parameter: the management of acute gastroenteritis in young children. Pediatrics 97(3), 424-435. [Abstract] [Free Full-text]
Armon, K., Stephenson, T., MacFaul, R. et al. (2001) An evidence and consensus based guideline for acute diarrhoea management. Archives of Disease in Childhood 85(2), 132-142. [Abstract] [Free Full-text]
Banks, M. and Farthing, M. (2003) Acute diarrhoea: guide to current management. Prescriber 14(20), 48-60.
Baxter, K. (Ed.) (2008) Stockley's drug interactions: a source book of interactions, their mechanisms, clinical importance and management. 8th edn. London: Pharmaceutical Press.
Blaser, M.J. and Allos, B.M. (2005) Chapter 213: Campylobacter jejuni and related species. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases - Online.6th edn.Elsevier.www.ppidonline.com
BNF 57 (2009) British National Formulary. 57th edn. London: British Medical Association and Royal Pharmaceutical Society of Great Britain.
BNF for Children (2008) British National Formulary for children. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain.
CDC (2005a) Yersinia enterocolitica. ..Centers for Disease Control and Prevention.www.cdc.gov [Free Full-text]
CDC (2005b) Marine toxins. ..Centers for Disease Control and Prevention.www.cdc.gov [Free Full-text]
CDC (2008a) Campylobacter. ..Centers for Disease Control and Prevention.www.cdc.gov [Free Full-text]
CDC (2008b) "Crypto" - Cryptosporidiosis. ..Centers for Disease Control and Prevention.www.cdc.gov [Free Full-text]
CDC (2008c) Escherichia coli. ..Centers for Disease Control and Prevention.www.cdc.gov [Free Full-text]
CDC (2008d) Giardiasis. ..Centers for Disease Control and Prevention.www.cdc.gov [Free Full-text]
CDC (2008e) Salmonellosis. ..Centers for Disease Control and Prevention.www.cdc.gov [Free Full-text]
CDC (2008f) Shigellosis. ..Centers for Disease Control and Prevention.www.cdc.gov [Free Full-text]
CDC (2008g) Cryptosporidiosis - treatment. ..Centers for Disease Control and Prevention.www.cdc.gov [Free Full-text]
CDC (2009) Aflatoxin. ..Centers for Disease Control and Prevention.www.cdc.gov [Free Full-text]
Clinton White Jr., A. (2005) Chapter 280: Cryptosporidiosis (Cryptosporidium hominis, Cryptosporidium parvum, and other species). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases - Online.6th edn.Elsevier.www.ppidonline.com
CSM (1991) Convulsions due to quinolone antimicrobial agents. Current Problems in Pharmacovigilance 32(Oct), 2. [Free Full-text]
CSM (2002) Reminder: fluoroquinolone antibiotics and tendon disorders. Current Problems in Pharmacovigilance 28(Apr), 3-4. [Free Full-text]
CSM (2004) Statins and cytochrome P450 interactions. Current Problems in Pharmacovigilance 30(Oct), 1-2. [Free Full-text]
de Bruyn, G., Hahn, S. and Borwick, A. (2000) Antibiotic treatment for travellers' diarrhoea (Cochrane Review). The Cochrane Library.Issue 3.John Wiley & Sons, Ltd.www.thecochranelibrary.com [Free Full-text]
Dettmer, A. (1994) Loperamide oxide in the treatment of acute diarrhea in adults. Clinical Therapeutics 16(6), 972-980. [Abstract]
DH (2010) Health protection legislation (England) guidance 2010. ..Department of Health.www.dh.gov.uk [Free Full-text]
Dreverman, J.W. and Van der Poel, A.J. (1995) Loperamide oxide in acute diarrhoea: a double-blind, placebo-controlled trial. The Dutch Diarrhoea Trialists Group. Alimentary Pharmacology & Therapeutics 9(4), 441-446. [Abstract]
Dryden, M.S., Gabb, R.J. and Wright, S.K. (1996) Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin. Clinical Infectious Diseases 22(6), 1019-1025. [Abstract] [Free Full-text]
DuPont, H.L. (2005) Chapter 221: Shigella species (bacillary dysentery). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases - Online.6th edn.Elsevier.www.ppidonline.com
DuPont, H.L., Flores Sanchez, J., Ericsson, C.D. et al. (1990) Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea. American Journal of Medicine 88(6A), 15S-19S. [Abstract]
Ejemot, R.I., Ehiri, J.E., Meremikwu, M.M. and Critchley, J.A. (2008) Hand washing for preventing diarrhoea (Cochrane Review). The Cochrane Library.Issue 1.John Wiley & Sons, Ltd.www.thecochranelibrary.com [Free Full-text]
Ernst, A.A., Weiss, S.J., Park, S. et al. (2000) Prochlorperazine versus promethazine for uncomplicated nausea and vomiting in the emergency department: a randomized, double-blind clinical trial. Annals of Emergency Medicine 36(2), 89-94. [Abstract]
Farthing, M.J.G. (2003) Travellers' diarrhoea. Medicine 31(1), 35-40.
Farthing, M., Feldman, R., Finch, R. et al. (1996) The management of infective gastroenteritis in adults. A consensus statement by an expert panel convened by the British Society for the Study of Infection. Journal of Infection 33(3), 143-152.
Fry, A.M., Braden, C.R., Griffin, P.M. and Hughes, J.M. (2005) Chapter 95: Foodborne disease. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases - Online.6th edn.Elsevier.www.ppidonline.com
FSRH (2011) Drug interactions with hormonal contraception. ..Faculty of Sexual and Reproductive Healthcare.www.fsrh.org [Free Full-text]
Goodman, L.J., Trenholme, G.M., Kaplan, R.L. et al. (1990) Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Archives of Internal Medicine 150(3), 541-546. [Abstract]
Guerrant, R.L., Van Gilder, T., Steiner, T.S. et al. (2001) Practice guidelines for the management of infectious diarrhea. Clinical Infectious Diseases 32(3), 331-351. [Free Full-text]
Halvorson, H.A., Schlett, C.D. and Riddle, M.S. (2006) Postinfectious irritable bowel syndrome: a meta-analysis. American Journal of Gastroenterology 101(8), 1894-1899. [Abstract]
Health Protection Network (2008) Guidance for the public health management of infection with verotoxigenic escherichia coli (VTEC). Health Protection Network Scottish Guidance. ..Health Protection Scotland.www.hps.scot.nhs.uk [Free Full-text]
HPA (2007a) Infectious diarrhoea. The role of microbiological examination of faeces: quick reference guide for primary care. For consultation and local adaption. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2007b) E. coli O157. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2007c) Guidelines for the management of communicable diseases out of hours. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2008) Bacillus spp. - clinical information. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009a) NOIDS: reporting procedures. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009b) Campylobacter. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009c) Cryptosporidium. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009d) Entamoeba histolytica. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009e) Vero cytotoxin-producing Escherichia coli (VTEC) O157. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009f) Giardia. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009g) Salmonella. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009h) Shigella. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009i) Bacillus spp. food poisoning. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009j) General information - Staphylococcus aureus food poisoning. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009k) Staphylococcus aureus food poisoning. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009l) Yersinia. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009m) General information - Yersinia enterocolitica. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009n) Rotavirus. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009o) General information - Rotavirus. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009p) Norovirus. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009q) General information - Norovirus. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009r) Salmonella: factsheet. ..Health Protection Agency.www.hpa.org.uk
HPA (2009s) Campylobacter - clinical information. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009t) General information - Campylobacter. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2009u) Vero cytotoxin-producing Escherichia coli (VTEC) O157 - frequently asked questions. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2010) List of notifiable diseases. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
HPA (2011) The management of acute bloody diarrhoea potentially caused by vero cytotoxin producing Escherichia coli in children. ..Health Protection Agency.www.hpa.org.uk [Free Full-text]
Hsu, R.B. and Lin, F.Y. (2005) Risk factors for bacteraemia and endovascular infection due to non-typhoid salmonella: a reappraisal. QJM 98(11), 821-827. [Abstract] [Free Full-text]
Hughes, I.W. (1995) First-line treatment in acute non-dysenteric diarrhoea: clinical comparison of loperamide oxide, loperamide and placebo. UK Janssen Research Group of General Practitioners. British Journal of Clinical Practice 49(4), 181-185. [Abstract]
IFH Scientific Advisory Board (2001) Recommendations for selection of suitable hygiene procedures for use in the domestic environment. ..Intramed Communications.www.ifh-homehygiene.org [Free Full-text]
Independent Investigation Committee (2010) Review of the major outbreak of E. coli 0157 in Surrey, 2009. An evaluation of the outbreak and its management, with a consideration of the regulatory framework and control of risks relating to open farms. Report of the Independent Investigation Committee June 2010. ..Health Protection Agency.www.griffininvestigation.org.uk
Johnson, P.C., Ericsson, C.D., DuPont, H.L. et al. (1986) Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers' diarrhea. Journal of the American Medical Association 255(6), 757-760. [Abstract]
Jones, R. and Rubin, G. (2009) Acute diarrhoea in adults. BMJ 338, b1877.
Lennon, G., Cashman, O., Lane, K. et al. (2007) Prevalence and characterization of enteric adenoviruses in the South of Ireland. Journal of Medical Virology 79(10), 1518-1526. [Abstract]
Li, S.T., Grossman, D.C. and Cummings, P. (2007) Loperamide therapy for acute diarrhea in children: systematic review and meta-analysis. PLoS Medicine 4(3), e98. [Abstract] [Free Full-text]
Lustman, F., Walters, E.G., Shroff, N.E. and Akbar, F.A. (1987) Diphenoxylate hydrochloride (Lomotil) in the treatment of acute diarrhoea. British Journal of Clinical Practice 41(3), 648-651.
MHRA (2008) Statins: interactions, and updated advice for atorvastatin. Drug Safety Update 1(6), 2-4. [Free Full-text]
National Collaborating Centre for Women's and Children's Health (2009) Diarrhoea and vomiting caused by gastroenteritis: diagnosis, assessment and management in children younger than 5 years (full NICE guideline). .Clinical guideline 84.Royal College of Obstetricians and Gynaecologists.www.nice.org.uk [Free Full-text]
NICE (2009) Diarrhoea and vomiting in children under 5 (NICE guideline). ...www.nice.org.uk [Free Full-text]
NICE (2013) Key therapeutic topics - medicines management options for local implementation. ..National Institute for Health and Clinical Excellence.www.nice.org.uk [Free Full-text]
Noguerado, A., Garcia-Polo, I., Isasia, T. et al. (1995) Early single dose therapy with ofloxacin for empirical treatment of acute gastroenteritis: a randomised, placebo-controlled double-blind clinical trial. Journal of Antimicrobial Chemotherapy 36(4), 665-672. [Abstract]
NPC (2011) Key therapeutic topics 2010/11 - Medicines management options for local implementation. ..National Prescribing Centre.www.npc.nhs.uk [Free Full-text]
NPC (2012) Key therapeutic topics - medicines management options for local implementation. ..National Prescribing Centre.www.npc.nhs.uk [Free Full-text]
NTIS (2008a) Use of loperamide in pregnancy. TOXBASE..National Teratology Information Service.www.toxbase.org
NTIS (2008b) Use of azithromycin in pregnancy. TOXBASE..National Teratology Information Service.www.toxbase.org
NTIS (2008c) Use of erythromycin in pregnancy. TOXBASE..National Poisons Information Service.www.toxbase.org
Pegues, D.A., Ohl, M.E. and Miller, S.I. (2005) Chapter 220: Salmonella species, including Salmonella typhi. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases - Online.6th edn.Elsevier.www.ppidonline.com
PHLS Advisory Committee on Gastrointestinal Infections (2000) Guidelines for the control of infection with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Advisory Committee on Gastrointestinal Infections. Communicable Disease and Public Health 3(1), 14-23. [Abstract] [Free Full-text]
PHLS Advisory Committee on Gastrointestinal Infections (2004) Preventing person-to-person spread following gastrointestinal infections: guidelines for public health physicians and environmental health officers. Communicable Disease and Public Health 7(4), 362-384. [Abstract] [Free Full-text]
Ravdin, J.I. and Stauffer, W.M. (2005) Chapter 270: Entamoeba histolytica (Amebiasis). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases - Online.6th edn.Elsevier.www.ppidonline.com
Rees, J.H., Soudain, S.E., Gregson, N.A. and Hughes, R.A. (1995) Campylobacter jejuni infection and Guillain-Barré syndrome. New England Journal of Medicine 333(21), 1374-1379. [Abstract] [Free Full-text]
Safdar, N., Said, A., Gangnon, R.E. and Maki, D.G. (2002) Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. Journal of the American Medical Association 288(8), 996-1001. [Abstract] [Free Full-text]
Schaefer, C., Peters, P. and Miller, R.K. (Eds.) (2007) Drugs during pregnancy and lactation: treatment options and risk assessment. 2nd edn. Oxford: Academic Press.
Seller, R.H. (Ed.) (1996) Differential diagnosis of common complaints. 3rd edn. Philadelphia: W.B. Saunders.
Sirinavin, S. and Garner, P. (1999) Antibiotics for treating salmonella gut infections (Cochrane Review). The Cochrane Library.Issue 1.John Wiley & Sons, Ltd.www.thecochranelibrary.com [Free Full-text]
Spira, A.M. (2003) Assessment of travellers who return home ill. Lancet 361(9367), 1459-1469. [Abstract]
Swagerty, D.L., Walling, A.D. and Klein, R.M. (2002) Lactose intolerance. American Family Physician 65(9), 1845-1850. [Free Full-text]
Sweetman, S.C. (Ed.) (2005) Martindale: the complete drug reference. 34th edn. London: Pharmaceutical Press.
Taylor, D.N., Bourgeois, A.L., Ericsson, C.D. et al. (2006) A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. American Journal of Tropical Medicine and Hygiene 74(6), 1060-1066. [Abstract] [Free Full-text]
UKMiCentral (2004) Drugs in lactation. ..UKMiCentral.www.ukmicentral.nhs.uk [Free Full-text]
Van Den Eynden, B. and Spaepen, W. (1995) New approaches to the treatment of patients with acute, nonspecific diarrhea: a comparison of the effects of loperamide and loperamide oxide. Current Therapeutic Research, Clinical & Experimental 56(11), 1132-1141.
Walker-Smith, J.A. and Murch, S.H. (2003) Diarrhoea in childhood. Medicine 31(1), 41-44.
Wheeler, J.G., Sethi, D., Cowden, J.M. et al. (1999) Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance. British Medical Journal 318(7190), 1046-1050. [Abstract] [Free Full-text]
WHO (2003) The treatment of diarrhoea. ..World Health Organization.www.who.int
Wingate, D., Phillips, S.F., Lewis, S.J. et al. (2001) Guidelines for adults on self-medication for the treatment of acute diarrhoea. Alimentary Pharmacology & Therapeutics 15(6), 773-782. [Abstract] [Free Full-text]
World Gastroenterology Organisation (2008) Acute diarrhea. ..World Gastroenterology Organisation.www.worldgastroenterology.org [Free Full-text]